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INTRODUCTION 
Siddha system of medicine is one of the ancient traditional system practiced in 
southern peninsula of India. This system reflects the cultural practices and medical 
wisdom of the civilians of the land. .Apart from treating the diseases the Siddha 
system contributes more on preventing many maladies. 
Siddhars the originators of siddha medicine have taught us the virtues of a 
good  practitioners and led a simple life above the narrow division of creed, religion, 
colour, and nation.The simplest way for a healthy living is to live according to the 
laws of nature as emphasized by Siddhars who lived longer without any senile 
change. These noble people have not only contributed a system of medicine but also 
to explains the way to attain the eternal bliss, it is essential to have a healthy body 
 Siddhars explained the body as a whole is made up of five elements Earth, 
water, fire, air and Ether which are the fundamentals of creation, protection, and 
destruction. The drugs for treating disease have been procured from the plants, 
animal, and mineral origin. Various type of medicinal preparations such as gruels, 
powders, decotions, medicated ghee, oil, thailam, paste etc, are given vively. Such 
prepared drugs have the properties and qualities pertaining to panchabhootham .
 
The human body is conditioned by three humors consisting of Vaatham, 
pittham, Kabham. These three vital forces (Vaatham, Pitham, Kabam) of cosmic 
elements are named under the action or reaction of the panchaboothams.
6
 The 
deranging of this vital forces causes disease. Aim of this system of medicine is to 
balance the vital forces and setting right the equilibrium of the three energies 
   “Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ Ñ§Ä¡÷ 
ÅÇ¢Ó¾Ä¡ ±ñÉ¢Â ãýÚ”            -¾¢ÕÅûéÅ÷ 
 
In the text book of Siddha Maruthuvam Pothu, Vali Azhal Keel Vaayu is 
described in Sababathikaiyaedu ,among 10 types of   Keel Vaayu , ValiAzhal Keel 
Vaaayu is one of the type ,with symptoms of Indigesion , Sour Belching,  Distention 
of stomach, Constipation, Redness ,Burning sensation, Pain, in wrist joint, ankle joint 
and phalanges, pricking pain, swelling, burning sensation over the joints, is compared 
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to  symptoms of Rheumatoid Arthritis in modern science. Various siddha formulation 
has been mention in siddha literature to treat Vali Azhal Keel Vaayu. 
 Rheumatoid Arthritis (RA) is a most inflammatory disease of the joints, It is a 
systemic disease of the young and middle aged adults. Characterized by proliferation 
and destructive changes in synovial membrane, Periarticular structures, skeletal 
muscles and periarticular sheaths. Eventually joints are destroyed, fibrosed or 
ankylosed. 
 The prevalence of Rheumatoid Arthritis is ranges from 0.8% of the general 
population. Women are affected three times more often than men. Life risk of 
rheumatoid arthritis is estimated 4% among women and 3%among men. In India a 
local survey in Delhi shows the prevalence of this disease affecting 0.75% of 
population
 
 Patients diagnosed with Rheumatoid Arthritis visiting Ayothidoss Pandithar 
Siddha hospital considerably increasing for the past few years. There are many 
treatment modalities available in modern system especially with Non steroidal anti- 
inflammatory (NSAID) drugs, steroids and cytotoxic drugs to treat Vazhi Azhal Keel 
Vayu. Due to more adverse effects of these drugs the patients were suffering more 
than cure. So, author decided to find a new formulation for this ailment. 
I Investigator had selected Vaatha chooranam (Internal) and Vaatha Mega 
Narayana Ennai (External) for treating Vali Azhal Keel Vaayu (Rheumatoid Arthritis) 
Which is a polyherbal preparation to equalize the de-ranged Vaatham, Pitham and 
Kabam. The ingredient of the trial drug, Smilax china, Terminalia cebula, Acorus 
calamus, Piper longus possess Anti- inflammatory, Anti-oxidant property, Aanalgesic 
property. Hence this trial drug has been selectedfor the trail for treating Vali Azhal 
Keel Vaayu (Rheumatoid arthritis) 
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AIM 
To evaluate the therapeutic efficacy of siddha drugs “Vaatha Chooranam” 
(Internal) and “Vaatha Mega narayana Ennai” (External ) in the treatment of “Vali 
Azhal Keel Vayu” (Rheumatoid arthritis) 
OBJECTIVE 
PRIMARY OBJECTIVE 
To evaluvate the therapeutic efficacy of siddha drugs “Vaatha Chooranam” (Internal) 
and “ Vaatha Mega narayana Ennai” (External ) in reducing the pain and restricted 
movement in the treatment of  “Vali Azhal Keel Vayu” (Rheumatoid arthritis) 
SECONDARY OBJECTIVES 
 To study the siddha basic principles towards the efficacy of the medicine 
 To evaluate the safety of the trial drugs by doing toxicology studies Acute and 
Long term study 
 Biochemical analysis of the drug 
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VALI AZHAL KEEL VAAYU 
Synonym: Uthiravaathasuronitham, Mudakkuvaatham 
Siddha system of Medicine is an ancient one enriched with good resources. 
The sources of Siddha medicines include Herbs, Minerals, Metals and also animal 
origin.. 
Siddha system was propounded by the Siddhars is a vast and unique system 
which defines health as a perfect state of physical, psycho social, social and spiritual 
wellbeing of an individual. 
 The system not only deals with medicinal but with spirituality,righteous way 
of living, Rejuvenation and its main aim is attainment of perfection. 
“«ñ¼ò¾¢ÖûÇ§¾ À¢ñ¼õ 
À¢ñ¼ò¾¢ÖûÇ§¾ «ñ¼õ.” 
- ºð¼ ÓÉ¢ »¡Éõ. 
 The universe around as in the Macrocosm (Andam) and the human body is 
considered as the Microcosm (Pindam). Any changes in the Macrocosm will have its 
impact in the Microcosm in the human body. 
“¿¢Äó¾£ ¿£÷ÅÇ¢ Å¢Íõ§À¡ ¨¼óÐõ 
¸Äó¾ ÁÂì¸õ ¯Ä¸õ ¬¾Ä¢ý 
þÕ¾¢¨½ ³õÀ¡ø þÂ¦ÉÈ¢ ÅÆ¡ «¨Áò 
¾¢Ã¢Å¢ø ¦º¡ø¦Ä¡Î ¾Æ¡«ø §ÅñÎõ.” 
   -¦¾¡ø¸¡ôÀ¢Âõ ¦À¡Õû «¸Ã¡¾¢. 
 
The poet explains that both Andam and Pindam formed by the basic five 
elements called panchaboodhams. They are 
 1. Pirithivi (Earth) 
 2. Appu (Water) 
 3. Theyu (Fire) 
 4. Vaayu (Air) 
 5. Aahayam (Ether) 
These five elements combined to form Three Thathus. 
 1. Vaatham 
 2. Pitham 
 3. Kabam 
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These three thathu  composed of  
1. Vatham  = Air + Ether 
2. Pitham   = Fire 
3. Kabam   = Earth + water 
The physiological units of the Human body is otherwise called as Vali 
(Vatham), Azhal (Pitham) and Iyyam (Kabam). They are also formed by the 
combination of the five basic elements. Accordingly Vali is formed by the 
combination of Vayu (Air) and Aagayam (Space). This is the Creative force. Azhal is 
formed by theyu (Fire). This is the Force of Preservation. Iyyam is formed by 
Prithivi (Earth) and Appu (Water). This is the Force of Protection. These three 
humors are in the ratio of 4:2:1 in equilibrium which is a healthy normal condition 
and disturbance in their equilibrium leads to diseases. This is denoted in 
  "¦À¡í¸¢Â ¨¾óÐìÌû ¦À¡øÄ¡¾Ð þõ ãýÚ¾¡ý 
 ¾í¸¢Â Å¡Ô ºÁò¾ý Á¸¡Å¡¾õ 
  Àí¸¢Â ÅýÉ¢Â¡ø ÀÌó¾Ð À¢ò¾§Á 
  ÀÌó¾ ºÄò¾¢ø ÀÃ¢º¢ìÌõ ¿ø¨ÄÔõ 
  ÅÌó¾ þõãýÈ¡ø ÅÇ÷ó¾Ð §¿¡¦ÂøÄ¡õ 
  «Ìó¾Ð ¾¡ÉÈ¢óÐ «ÇÅ¢ð¼ §Â¡¸¢¸û 
  Á¸¢úó§¾ Â¢¾¢ø ¿¢ýÈ ÁÂì¸õ «È¢Å¡§È." 
 -À¾¢¦½ý º¢ò¾÷ ¿¡Ê º¡Š¾¢Ãõ 
These three thathus  perceived as Naadi which is unique feature of Siddha 
system.When the above three humours are affected (or) not in a balanced state , they 
become Kuttram which predisposes to diseases. 
I. Vali (Vaatham) 
These active elements are always supported by the two stable elements, for 
change can only happen upon the foundation of stable. Thus Vayu and Aahaayam 
combine to become “Vaathamhumor” which controls all aspects of movements as 
well as space with in the body. In spite of this combination, however, Vaatham sends 
to primarily display the characteristics of Vayu-Air. The words“Dry, light, cold, 
quick, rough, minute and mobile” describes  the characteristics of  Vaatham. 
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II. Azhal (Pitham) 
This is the function that governs all the body‟s conversion processes as well as 
its heat and energy producing capacities. Pitham is primarily characterized by the 
qualities of Theyu, which are “hot, sharp, penetrating, light, acidic, and slightly oily”. 
III. Iyyam (Kabam): 
It controls liquefaction, lubrication and cohesion. It is also responsible for 
giving solidity and structure to the body. Kabam primarily reflects the qualities of the 
water, but also some traits of the earth elements, consequently, Kabam is heavy, slow, 
cold, steady, solid and oily. 
 
  ARTHRITIS – MOOTTU VAATHAM 
Arthritis is a group of conditions involving damage to the joint of the body. 
There are over 100 different forms of arthritis. Excess of vaatham affects the joints all 
over the body and Vitiation of Kabam causes indigestion. Thus the end product of 
digestion associated with vaatham, pitham, kabam blocks the tissue pores and 
passages with waxy material. It also affects simultaneously the joints of the body such 
as knee, shoulder, hip, neck etc. This produces the stiffness of the joints. Hence it is 
also known as Mudakkuvatham. 
       VALI AZHAL KEEL VAAYU  
Definition (Iyal) 
Valiazhal keel vaayu is defined asincrease in vaatham and pithakutram, 
charecterised by pain in joints, swelling, tenderness, caused by various causes as 
mentioned below  
AETIOLOGY : 
1. According to YugiVaithyaSinthamani, 
"±ýÉ§Å Å¡¾ó¾¡ ¦ÉñÀ ¾¡Ìõ 
  Á¢Ìò¾¢§Ä ÁÉ¢¾÷¸Ùì ¦¸öÐ Á¡Ú 
 À¢ýÉ§Å ¦À¡ó¾¨É§Â §º¡Ãï ¦ºöÐ 
  ¦ÀÃ¢§Â¡÷¸û À¢Ã¡Á½¨Ãò à‰ ½¢òÐõ 
ÅýÉ§ÅÅî¦º¡ò¾¢ü §º¡Ãï ¦ºöÐ 
  Á¡¾¡À¢¾¡ ÌÕ¨Å ÁÈó¾ §À÷ìÌõ  
¸ýÉ§Å §Å¾ò¨¾ ¿¢ó¨¾¦ºö¾ §À÷ìÌí 
  ¸¡Âò¾¢ü ¸Äó¾¢Î§Á Å¡¾ó ¾¡§É.” 
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"¾¡¦ÉýÈ ¸ºô§À¡Î ÐÅ÷ôÒ ¨ÃôÒ 
  º¡¾¸Á¡ö Á¢ïÍ¸¢Ûï º¨Áò¾ ÅýÉõ 
 ¬¦ÉýÈ Å¡È¢ÉÐ ¦À¡º¢ò¾ Ä¡Öõ 
  ¬¸¡ò §¾ÈÄÐ ÌÊò¾ Ä¡Öõ 
 À¡¦ÉýÈ À¸ÖÈì¸ Á¢Ã¡Å¢ Æ¢ôÒ 
  ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã ¦Áö¾ø 
 §¾¦ÉýÈ ¦Á¡Æ¢Â¡ü §Áü º¢ó¨¾ Â¡¸¢ø 
  º£ì¸¢ÃÁ¡ö Å¡¾ÁÐ ¦ºÉ¢ìÌó ¾¡§É." 
"¬½¡É ÅÃýÈ¦Éª§Â Á¾¢Â¡ Á¡ó¾÷ 
    «¸¾¢ÀÃ §¾º¢Â÷¸ð ¸ýÉ Á£Â¡÷ 
   §¸¡É¡É ÌÃ¦Á¡Æ¢¨Â ÁÈó¾ §À÷¸û 
    ¦¸¡¨Ä¸Ç× ¦À¡ö¸¡Áí ÌÈ¢ò¾ §À÷ìÌ 
   °É¡É º¼ó¾ýÉ¢ø Å¡¾õ ÅóÐ 
    ¯üÀÅ¢ìÌõ §Å¾ò¾¢ Öñ¨Á ¾¡§É." 
- ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
According to the saint Yugi‟s text, those who are squandering money, 
insulting the elders, blaspheming the Holy books, not respecting the divine gifts, 
abandoning or forgetting the parents having wickedness in their mind and those with 
sleeping in the day time and awake up during night will get Vaatham diseases, hot 
taste, increased intake of water,excessive starvation, Increased intake of bitter and 
astringent taste, increased sexual indulgence desire will produce Vaatha diseases. 
FACTORS THAT INFLUENCE THE VATHA TYPE OF DISEASES: 
¸¡Ä þÂøÒ – Environmental Factors: 
Relation between occurrence of Vaatha Diseases and Seasonal variations: 
“¬ÊÂ¡¾¢Â¡ö ³ôÀº¢ ®È¡ö 
  «É¢ÄÁ¾ü §¸¡ÃÃº¢Âø ¸¡Äõ.” 
Vaatham elevates in the body from the month of Aadi to Iyppasi (July to 
September)i,e from the middle of Muthuvenilkaalam,Kaarkaalam to half of 
Koothirkaalam. 
 To summarise, Vaatha diseases occur due to certain diet capable of increasing 
vatham, certain habits and environmental changes which elevates vatham. 
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Diet 
"¦¾¡Æ¢ø¦ÀÚ ¨¸ôÒì¸¡÷ò¾ø ÐÅ÷ò¾ø Å¢ïÍ¸¢Ûï 
 §º¡Õõ ¸¨ÆÂ¾¡õ ÅÃÌ Áü¨Èô¨Àó¾¢¨É ÂÕó¾¢É¡Öõ 
 ±Æ¢ø ¦ÀÈôÀ¸ÖÈí¸¢ þÃÅ¢É¢ÖÈí ¸¡¾¾¡Öõ 
 Á¨Æ ¿¢¸÷ ÌÆÄ¢É¡§Ä Å¡¾í§¸¡ À¢ìÌí ¸¡§½." 
                              -   ÀÃÃ¡º §º¸Ãõ 
According to Pararasa sekeram, excess consumption of bitter taste, astringents 
and sour tastes, increased intake of old cooked rice, intake of grains, day time sleep 
and wake up at night time will  get Vaatham diaeases. 
CLINICAL FEATURES OF UTHIRAVATHA SURONITHAM: 
“¨Å¸¢¾Á¡öì ¸¨½ì¸¡Ö ÓÆí¸¡ø ¾¡Ûõ 
   Áü¸¼ì ºóÐÒÈÅÊÔõÅ£í¸¢î 
¦ºö¸¢¾ Á¡ü º¢ÚÅ¢Ãø¸û Á¢¸×õ ¦¿¡óÐ 
   º¢ó¨¾ ¾ÎÁ¡È¢§Â ºÄ¢ôÒñ¼¡Ìõ 
¨À¸¢¾Á¡õ ÀÂ¢ò¾¢Âò ¾¢øÄ¡¾ Á¢ïº¢ô 
   À¡ÃÁ¡ö ¯üÀÅ¢òÐ «ÆÖñ¼¡Ìõ 
¯ö¸¢¾Á¡õ «ºÉÁÐ ¾¡Ûõ §Åñ¼¡ 
  ¯¾¢Ã Å¡¾ Í§Ã¡½¢¾ò¾¢ Û½÷îº¢Â¡§Á.” 
-ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
   It is characterised by pain and swelling in both ankle joints, knee joints and all 
smaller joints of the hands, feeling of tiredness, fever, loss of appetite and mental 
depression. 
         Also the term „Markadam‟ (Áü¸¼õ) indicates the hand of monkey 
(T.V.SampasivamPillai dictionary Pg no: 753) anatomically which can be correlated 
clinically with Swan neck deformity and wasting of thenar muscle in Rheumatoid 
Arthritis.   
2. THE CLINICAL FEATURES OF UTHIRAVATHA SURONITHAM IN 
„PARA RASA SEKARAM‟: 
“Àì¸Óõ Á¡÷Òõ Ü¼ôÀüÈ¢§Â þØòÐì ¦¸¡ñÎ 
¦¿ì¸¢§Â Á¡÷À¢¨ÇòÐ §¾¡¾¡ö ¿ÃõÀ¢ØòÐ 
´ì¸§Å ºÂ¢ò¾¢Âí¸û ¯Â÷óÐ¼ý §ÁÖõ ¸¡Äõ 
Á¢ìÌ§Á ¯¾¢ÃÅ¡¾õ ±ýÈ¢ÐÅ¢ÇõÀÄ¡§Á.” 
       -   ÀÃÃ¡º §º¸Ãõ 
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It is characterised by pain and tenderness of the axilla, breathlessness, pain in 
the upper limbs and the lower limbs. 
 
§¿¡öì¸½¢ôÒ ( DIAGNOSIS) 
 
"§¿¡ö¿¡Ê §¿¡öÓ¾ É¡Ê ÂÐ¾½¢ìÌõ 
Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø." 
      -¾¢ÕìÌÈû. 
 This Thirukural quote explains the importance of diagnosis as it is to be made 
in order of the aetiology, root of cause of the disease thereby treating the disease with 
appropriate medicine.  
Piniyarimuraigal (Method of Diagnosis) 
Piniyarimuraigal (Method of Diagnosis) is based upon the three main principles: 
 PoriyalArithal (Inspection) 
 PulanalArithal (Palpation) 
 Vinaathal (Interrogation) 
Poriyalarithal (Inspection): 
“Poriyalarithal” means examining the “Pori” of the patient by the physician 
for proper diagnosis. 
 Pori -five sense organs. 
 They are as follows, 
 Nose  
  Tongue  
  Eye  
  Skin   
  Ear. 
 
2. Pulanalarithal (Palpation): 
“Pulanalarithal” means examining the “Pulan” of the patient by the physician 
to diagnosis a disease. 
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Pulan-  senses 
  They are, 
 Smell 
 Taste 
 Vision 
 Sensation of touch 
 Hearing 
3. Vinaathal (Interrogation): 
Vinaathal is gathering of information about the history of the disease, its 
clinical features etc., from the patient or his close relatives who are taking care of 
them. Vinaathal is helpful when the patient is not in a position to speak or when the 
patient is child. 
Types of Naadi (Pulse) felt in Valiazhal keel vaayu: 
  In Siddha system of Medicine “Naadi diagnosis (Pulse reading)” is the first 
and foremost diagnostic parameter. 
 In Valiazhal keel vaayu the following types of Naadi can be commonly seen. 
They are,  
 Vaatha pitham 
 Vaatha kabam 
 Pitha vaatham 
 Kaba vaatham 
DIFFERENTIAL DIAGNOSIS 
Valiazhal keel vaayu is differentiated from other types of Vatha Suronitham as 
follows: 
S.NO DISEASES SIGNS AND SYMPTOMS 
1. Vaatha Suronitham  Emaciation. 
 Swelling of joints. 
 Restricted movements. 
 Joint pain. 
 Discomfort. 
 Excessive salivation. 
 Loss of appetite. 
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2. Sithuvatha Suronitham  Anasarca. 
 Wrinkles. 
 Neural pain. 
 Glossy tongue. 
 Sialorrhoea. 
 Bullous eruption as in burn. 
 Exfoliation, swelling  and 
Warmthness. 
3. Vaikitha Vaatha 
Suronitham 
 Swelling with hyperaemia. 
 Soft on touch. 
 Cough with pyrexia. 
 Irritability. 
4. Paithiya Vaatha 
Suronitham 
 Hyperaemia. 
 Tenderness in knee, elbow and 
smaller joints. 
 Poly arthralgia. 
 Pyrexia. 
 Anaemia. 
5. Slethuma vaatha 
Suronitham 
 Chillness with abdominal distension. 
 Severe pain and Head ache. 
 Syncope and Hallucination. 
 Dryness of mouth and Anorexia. 
 Tachycardia. 
6. Utharavaatha 
Suronitham 
 Fever with rigor. 
 Dryness of mouth. 
 Pain in all over the joints. 
 Headache. 
 Diarrhoea. 
 Excessive thirst. 
 Hunger. 
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LINE OF TREATMENT 
In Siddha system, the treatment is based upon the Mukkutram principle. 
Treatment is not only for perfect healing but also for the Prevention of disease 
progression and Rejuvenation of Udalkattugal. 
While treating a disease, it is essential to know the etiology, the nature of the 
patient, severity of the illness, the seasons and the time of occurrence.  
Line of treatment is as follows: 
Kappu (Prevention) 
Neekkam (Treatment) 
Niraivu (Restoration)  
I.KAAPPU (PREVENTION): 
“Prevention is better than cure” is a proverb. Knowing the cause there by 
removing it and thus preventing the disease is the main aim of Siddha system of 
medicine. 
Siddha system emphasizes the purification of thought and activities in the 
underlyinglines quoted from the text “Theraiyar Pinianuga Vithi” which 
emphasizes virtueness to be followed even in the daily life activities. i.e., 
À¡Öñ§À¡õ ±ñ¦½ö¦ÀÈ¢ý ¦Åó¿£÷ ÌÇ¢ô§À¡õ 
 À¸üÒ½§Ã¡õ; À¸üÚÂ¢ø§Å¡õ: À¡§Â¡¾ÃÓ ãò¾ 
 ²Äï§º÷ ÌÆÄ¢Â§Ã¡Ê Ç¦ÅÂ¢Öõ Å¢Õõ§À¡õ; 
 þÃñ¼¼ì§¸¡õ; ´ý¨ÃÅ¢§¼¡õ; þ¼Ð¨¸Â¢ü ÀÎô§À¡õ; 
2.NEEKAM (TREATMENT IN SIDDHA): 
The aim of treatment is based on, 
a) To bring the Three Thodams to normal equilibrium state. 
b) To treat the patient by Internal and external medicines. 
c) To stabilize 7 Udalthadhukal and 3 Uyirthadhukal. 
To bring the three Thodams to normal equilibrium state first by giving purgation. 
Diet Restrictions (Pathiyam): 
During the course of treatment, the patients were advised to follow certain 
dietary regimen (Ichapathiyam) which is mentioned for vaatha diseases. 
1. Kadugu 
2. Ell Nei 
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3. Kalyana Poosanikkai 
4. Kadalai 
5. Thengai 
6. Mangai 
7. Poondu 
8. Pala 
9. Kollu 
10.Pugaiyilai 
11. Pagal 
          12. Agathi 
13. Sour taste 
14. Astringent taste 
3. NIRAIVU (RESTORATION): 
Reassurance from disease recovery was given to all patients by promoting the 
awareness about the dietary, seasonal, emotional influence on the disease. Life-style 
modification was also advised to them. 
YOGAM FOR UTHIRAVATHA SURONITHAM: 
The patients are advised to do the following Yogasanas regularly. 
 Poorna santhi asanam 
 Mathriga pranayamam 
In case of sleep disturbances and depression: 
Nithirai pranayamam and Dhiyanam. 
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MODERN ASPECT 
RHEUMATOID ARTHRITIS 
INTRODUCTION 
Rheumatoid arthritis (RA) is chronic multi system disease of unknown etiology that 
primarily targets synovial joint and hence an important cause of potentially preventable 
disability. Although there are a variety of systemic manifestations the characteristic feature 
of(RA) is persistent inflammatory synovitis, usually involving pheripheral joints in a symmetric 
distribution. The potential of the synovial inflammation to cause cartilage damage, bone erosion  
and subsequent changes in joint integrity is the hallmark of the disease 
 
Epidemiology and genetics 
 The prevalence of RA is approximately 0.8% of the population (range 0.3to 2.1%), for 
reasons that are still unclear the prevalence in women is two or three times greater than in men. 
The onset is most frequent during the fourth and fifth decades of life with 80% of all patients 
developing the disease between the age of 35 and 50.the incidence of (RA) is more than six times 
greater in 60-64 old yr old women compared to 18-29 year old women. Since the incidence of 
(RA)  is stable with age  RA is a lifelong disease.
 
 
Genetic clearly play a significant role in determining both the risk of developing ra and 
the severity of the disease. The association of certain human leukocyte antigen (HLA) alleles, 
specifically HLA-DR4, and an increasing risk of developing ra has been long been recognized
5
.  
Pathogenesis 
RA appears to require the complex interaction of genetic and environmental factors with 
the immune system and ultimately the synovial tissues throughout the body. 
Microvascular injury and an increased in the number of synovial lining cells appear to be 
the earliest lesion in the RA. An increased number of synovial lining cells is seen along with 
perivascular infiltration with mononuclear cells, before the onset of clinical symptoms the 
perivascular infiltration is predominantly composed of myeloid cells, whereas in symptomatic 
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arthritis, T cells can also be found. As the process continues the synovium become oedematous, 
protrudes, in to joint cavity as villous projection.
 
 The endothelial cells of the rheumatoid synovium have the appearance of high 
endothelial venules of lymphoid organs and have been altered by cytokines exposure to facilitate 
entry of cells in to tissue. The mononuclear cell collections are variable in composition and size. 
The pre- dominant infiltration cell is the T LYMOPCYTE CD4+ T CELLS predominate over 
CD8+ TCELLS and frequently found in close proximity to HLA-DR+ macrophage and dendritic 
cells. The major population ofT cells in the rheumatoid synovium is composed of CD4+memory 
cells that form the majority of the cells aggregated around postcapillary venules.CD8+ cells are 
scattered throughout the tissues. Besides infiltration of T cells there is infiltration of B cells and 
antibody producing plasma cells. 
In advanced disease, structures similar to germinal centres of secondary lymphoid organs 
may be observed in the synovium. 
Both polyclonal immunoglobulin and autoantibody rheumatoid factor are produced 
within the synovial tissue, high leads to the local formation of rheumatoid synovium. Increased 
number of activated mast cells are found in the rheumatoid synovium, local release of the content 
and presence of antibodies leads to inflammation. 
The synovia fibroblast in the RA manifest evidence of activation of fibroblast in RA 
manifest evidence of activation and produce a number of enzymes such as collagenase and 
cathepsins that can degrade components of the articular matrix, this fibroblast are found 
prominently in the lining layer and at the interface in the bone and cartilage. Osteoclast are found 
at the site of bone erosion. 
The rheumatoid synovium is characterized by the presence of secreted products of 
activated lymphocytes, macrophages and fibroblast. The local production of these cytokines and 
chemokines appears to account for many of the pathological and clinical manifestation in RA 
including synovial inflammation, synovial fluid inflammation synovial proliferation, and 
cartilage and bone damage as well as systemic manifestation of RA 
 
MODERN ASPECT 
 
 
 Page 16 
 
CLINICAL MANIFESTATIONS 
 Pain ,Swelling, Tenderness 
 Morning Stiffness more than one hour 
 
OTHER CONSTITUTIONAL SYMPTOMS 
 Weakness 
 Fatigability 
 Anorexia 
 Weight loss 
AURTICULAR-MANIFESTATION 
 
DEFORMITY 
 
PATHOLOGY 
 
CAUSE 
Spindling of 
fingers 
Swelling of proximal 
interphalangeal joints 
Due to thickened synovial membrane leads 
to cartilage erosion causing spindling 
Swan neck 
deformity 
 Hyperextension of the 
proximal interphalangeal 
joint and flexion of the distal 
inter phalangeal joint 
Due to rupture of volar plate of 
PIP joints, which enablethe tendon to slip 
towards the dorsal side. This is known as  
Intrinsic pulse deformity  
Boutonniere 
or Button hole 
deformity 
Flexion of proximal 
interphalangeal joints and 
extension of the distal 
interphalangeal joint 
rupture e of central extensor expansion of 
the fingers  resulting  in flexion of PIP 
joint 
Drooped finger Patial or complete loss of 
voluntary extension, hyper 
extension of  the middle 
jointin an effort to extend 
the distal phalanges 
Extensor tendon rheumatoid granulomata  
and tendon rupture 
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FOOT DEFORMITIES: 
Callosity under PIP joint 
Plantar callosity 
Atrophy of plantar metatarsal fat pad 
Prominent metatarsal head  
Claw toes  
Hammer toes 
Rheumatoid nodules 
Achilles tendinitis 
Flattening of longitudinal arch 
Hallux valgus 
Overriding of second and third toes 
 
 
DEFORMITY 
 
PATHOLOGY 
 
CAUSES 
 
Trigger finger or 
tenosynovitis  
 
Locking of the finger in a 
position of flexion. 
 
The sheath of a flexor tendon 
thickens, apparently spontaneously 
to entrap the tendon 
 
 
 
Ulnar deviation  
Swelling of the meta carpo 
phalangeal joints, the big 
knuckles at the base of the 
fingers causes the fingers to 
become displaced, tending 
towards the little finger. 
 
Rupture of the collateral ligament at 
meta carpo phalangeal joints which 
enables extensor tendon to slip from 
their grooves towards the ulnar side 
MODERN ASPECT 
 
 
 Page 18 
 
EXTRA-ARTICULAR MANIFESTATION 
 
DIAGNOSIS 
Diagnosis of RA should be consider in patients with bilateral symmetrical, inflammatory 
polyarthritis involving small and large joints  with sparing of the axial skeleton except the 
cervical spine 
CRITERIA FOR DIAGNOSIS EULAR 
A. JOINT INVOLVEMENT 
 
One large joint 
2-10 large joints 
1-3 small joints 
4-10 small joints 
>10 joints 
 
 
Rheumatoid nodules 
 
 
They are round masses felt in sub cutaneous tissue 
mainly in Olecranon bursa, the proximal ulna, the 
Achilles tendon.etc 
 
Rheumatoid vasculitis 
Polyneuropathy and mononeuritis multiplex, 
cutaneous ulceration, palpable purpurae 
Pleuro pulmonary manifestation Pleural effusion, Interstitial fibrosis, Pneumoconiosis 
Cardiovascular manifestation Pericarditis, Pre-mature atherosclerosis, valvular 
involvement, conduction defects 
Neurological manifestation Capal and tarsal tunnel syndrome,  Spinal 
Compression , Peripheral neuropathies 
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 B. Serology 
 Negative RF and negative anti-citrulinated protein antibodies 
Low –positive RF for low ACPA 
High-positive RF for high positive ACPA 
Acute-phase reactants 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR 
Duration of symptoms 
<6weeks 
≤ weeks 
 
INVESTIGATION 
Markers of acute –inflammation-raised ESR, anaemia, thrombocytosis, increased level of 
acute phase protein, C-reactive protein and increased plasma viscosity 
Rheumatoid factor 
Anti-cyclic citrulinated protein antibodies 
Radiographs of the affected joint  
Ultrasonography and MRI  
Synovial fluid analysis, synovial biopsy arthroscopy 
RHEUMATOID FACTOR (RFs) 
Rheumatoid factor are IgM and IgG autoantibodies against the Fc portion of IgG . RF is present 
in about 80% of patient with RA it can also be found in number of other disease. RF testing is 
appropriate in patient suspected of having RA. RF is a good screening tool. In patient with RA, 
RF titre generally correlates with extra-articular manifestation and disease severity. However RF 
titre is not useful in following disease progression. Hence, if a patient is RF positive there is no 
need to repeat it later. 
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MANAGEMENT 
Rest and splinting of the joints should be instituted in acute stage of illness 
Active and passive physiotherapy helps in mobilization and prevention of contracture 
Analgesics Medicines 
Modifying Anti-rheumatic drugs 
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PROPERTIES OF TRIAL DRUG 
 
INTERNAL DRUG : VAATHA CHOORANAM 
PARANGI PATTAI 
Botanical name : smilax china 
Family  : Smilaceae 
Parts used  : Rhizome 
Organoleptic characters  
Taste   : Sweet 
Potency  : Cold 
Division  : Sweet 
Action   : Anti-inflammatory, Anti cancer, Anticoagulation 
General characters 
¾¡¸õ ÀÄÅ¡¾ö ¾¡Ð ÒñÀ¢Ç¨Å 
§Á¸í ¸Ê¸¢Ãó¾¢ Å£úãÄó-§¾¸Ó¼ý 
Ìð¨¼ À¸ó¾§Áü ¦¸¡ûÅÁÉõ §À¡õÀÈ 
Àí¸¢Â¢¨É ÔîºÃ£òÐô À¡÷      
- «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
Medicinal uses: It is indicated for treating veneral disease, rheumatism, Chronic skin 
infection 
ATHIMATHURAM  
 
Botanical name :    Glycyrrhiza glabra 
Family  : Fabaceae 
Parts used  : Root 
Organoleptic characters 
Taste   : Sweet, Bitter 
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Potency  : Cold 
Division  :  Acrid  
Activity  : Glycyrrhizin, Glycerrhizin 
General character 
¨¸ò¾¢ÂÃ¢ ÓôÀ:¢½¢Â¡ø ÅÕÒñ ¾¡¨¸í 
¸ñ§½¡ö ¯ý Á¡¾õÅ¢ì¸ø ÅÄ¢¦Åñ Ìð¼õ 
À¢ò¾¦ÁÖõ ÒÕì¸¢ ¸¢Ã¢îºÃõ ¬Å÷ò¾ 
À¢ò¾Á¾ ã÷î¨º Å¢¼ À¡¸õ ¦ÅôÀó¾½¢ìÌõ 
 «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
Medicinal Uses: 
This drug is useful in treating gastric and duodenal ulcer asthma, hypertension, 
rheumatoid arthritis and dermatitis 
 
KADUKKAI   
 
Botanical name :         Terminalia chebulla 
Family  : Combretaceae 
Parts used  : Fruit 
Organoleptic characters 
Taste   : Sweet, Astringent, Sour, Bitter, Pungent 
Potency  : Cold 
Division  :  Acrid 
Action   :  Laxative, Hypolipidaemic, Antioxidant, Hepato Protective,  
Adaptogenic and Cardiac activates are present in this drug. 
General character: 
¾¡¨¼ ¸Øò¾ì¸¢ ¾¡Ö ÌÈ¢Â¢Å¢¼ô 
À£¨¼ º¢Ä¢À¾Óü §À¡¾¢Ó¼õ ¬¨¼ö¦Âð¼¡ò 
àÄÁ¢Ê ÒñÅ¡¾ §º¡½¢¸¡ Á¡¨ÄÂ¢Ãñ 
¼¡ÄÁ¢Ê §À¡õÅÃ¢ì¸¡ Â¡ø 
 «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
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Medicinal uses: 
It is used in treating inflammation of mucous membrane of mouth and scalds, 
muscular rheumatism ,jaundice, abdominal distention, etc.Aqueous extract showed 
antioxidant and radio protector properties 
 
 NELLIKAI 
 
Botanical name  :  Phyllanthus emblica 
Family  : Euphorbiaceae  
Parts used  : Fruit 
Organoleptic characters 
Taste   : Sour, Astringent, Sweet  
Potency  : Cold 
Division  :  Sweet 
Action   : Refrigerant, Diuretic, Laxative 
Medicinal uses :  It has antioxident with free radical scavenging properties,  
Hepatoprotective, Antimutagenic, anti microbial  activities. 
General charecter; 
¬¸ÅÉ Äïº¢ º¢÷ì¦¸ýÒÕì ¸¢ñ§½¡ö 
¾¡¸ Ó¾¢ÃÅÅ¢ò¾ó ¾¡Ð ¿ð¼õ- §Á¸Éò¾¢ý 
þøÄ¢ÓûÇ¢ §À¡ÄÕ¨¸ø «ñ¸¡ Á¢ÂÅ¢¨Âí¸õ 
¦¿øÄ¢ÓûÇ¢ Â¡ü§À¡ ¿¢¨É  
§¾¨ÃÂ÷ Ì½Å¡¸¼õ 
 
THANDRIKAI 
Botanical name     : Terminalia bellirica 
Family                    :  Combretaceae   
Parts used  : Fruit   
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Organoleptic characters 
Taste   : Astringent 
 Potency  : Hot  
Division  :  Sweet  
Action   : Astringent, Expectorant, Laxative, Tonic . 
General character 
º¢Äó¾¢Å¢¼õ ¸Á¢ÂôÒñ º£Æ¡É §Á¸í 
¸ÄóÐÅÕõ Å¡¾ÀÀ¢ò¾í ¸¡§Ä¡- ¼¨Ä÷óÐ¼Ä¢ø 
°ýÈ¢ì¸¡ö ¦ÅôÀ Ó¾¢ÃÀ¢ò Ðí¸ÃìÌó 
¾¡ýÈ¢ì¸¡ö ¨¸Â¢¦ÄÎò ¾¡ø 
 «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
 
Medicinal uses: Bile-stimulant activity, Anti-micribial activity, Hepatoprotective, 
hypolipidemic activity, It is useful in treating stomach disorders, dropsy, leprosy 
 
POOLAN KIZHANGU  
Botanical name     :  Kaemifera galanga 
Family  :  Zingiberaceae   
Parts used  :  Fruit 
Organoleptic characters 
Taste   : Sweet, Sour, Astringent 
Potency  : Cold 
Division  :  Sweet 
Action   : Refrigerant, Diuretic, Laxative carminative, stimulant 
General characters: 
µðÎõ ¿ü ¸¢îº¢Ä¢Â¢ ¦½¡ñ¸¢ÆíÌí ¸ÀÓõ 
  âðÎÓ¼ÓõÒñÏõ §À¡õ”  
«¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
 
Medicinal uses : Hypolipidaemic, wound healing, hepatoprotective, antibacterial, Anti-
fungal
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KIRAMBU 
 
Botanical name : Syzygium aromaticum 
Family  : Mytraceae  
Parts used  : dried bud  
Organoleptic characters 
Taste   : Pungent 
Potency  : Hot 
Division  :  Pungent 
Actions  : Antispasmodic, Carminative ,Stomachic 
General charecters 
À¢ò¾ÁÂì¸õ §À¾¢§Â¡Î Å¡ó¾¢Ôõ§À¡õ 
Íò¾Å¢Ãò ¾ì¸ÎôÒó §¾¡ýÚ§Á¡ ¦Áò¾  
þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
ÁÄÁí§¸ ¸ðÎ¦ÁÉÅ¡úòÐ. 
 «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
 
DHEVATHARAM 
 
Botanical name : Cedrus deodra 
Family  : Pinaceae  
Parts used  : wood   
Organoleptic characters: 
Taste   : astringent 
Potency  : Hot 
Division  :  Pungent 
Action   : Anti-inflammatory activity.  
 
 
DRUG REVIEW 
 
 Page 26 
 
General Charecter 
§¾Å¾¡ ÃìÌ½óÐÅÇ÷ À£É¢ºò¨¾ì 
¸¡Å¸ò¾¢ §Ä¡ðÎí ¸ÃôÀÄ§Å-Á¡ÅÄÅ÷ 
¦º¡øÖõÒ Ã¡½ ÍÃ¦Á¡Î ¿£§ÃüÈò¨¾ 
¦ÅøÖ ÁÉüÈ½¢ìÌ ¦Áö 
 «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
 
Medicinal uses:  Used in the treatment of rheumatoid arthritis 
 
ATHIVIDAYAM   
Botanical name : Aconitum heterophyllam 
Family  : Ranunculaceae  
Parts used  : root  
Organoleptic characters 
Taste   : Bitter 
Potency  : Hot 
Division  :  Pungent 
General character 
«¾¢Å¢¼Âõº÷ì¸ Ã¡üÒ¾§¿¡ö ¦ÅôÒ 
¦¸¡¾¢ÁÕ× §À¾¢¦Â¡Î §¸¡¨Æ-±¾¢÷Å¡ó¾¢ 
±ýÚ¨ÃìÌõ §¿¡öÜð¼õ þøÄ¡ ¾¸üÈ¢Å¢Îõ 
Ìý¨È ¿¢¸÷Ó¨ÄÂ¡ö ÜÚ. 
  «¸ò¾¢Â÷ ÌÉÅ¡¸¼õ 
Action   : Anti-inflammatory and analgesic. 
Phyto chemicals :  alkaloid, aconitine, alkaloidatisine, hetratisin, hetisine, and  
heterophylline. 
Medicinal uses :  Aconitine is used externally in neurolgia, rheumatism . 
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CHUKKU 
 
Botanical name : Zingiber officinale 
Family  : zingiberaceare  
Useful part  : Rizome 
Organoleptic characters 
Taste   : Pungent 
Potency  : Hot 
Division  :  Pungent 
Action   : Anti ulcer, Antifungal, Anti –oxidant activity 
Phytochemicals :  Gingerol 
General charecters: 
Ý¨ÄÁó¾õ ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷-Å¡Ä¸À 
§¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
§¾¡¼õ¬ Áõ§À¡ìÌïÍìÌ. 
 
Medicinal uses: It is used to treat dyspepsia, throat complaint , chronic rheumatism, 
gastro intestinal and respiratory disease. 
THIPPILI 
Botanical Name : Piper longum 
Synonym   : Charicaroxburgii 
Family  : Piperacae 
Organoleptic Character 
Taste   : pungent 
Potency  : Hot 
Division  : Pungent 
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  - 
   
  –  
 
Phyto chemicals: 
 Piperine (4– 5%), Volatile Oil, Piperlonguminine, Piplartine, Sesamin, 
Terpenoids, Resin, Piperundecalidine. 
  
Actions: 
 Stimulant 
 Carminative 
 Alterative 
 
Medicinal uses : It used in treating cough, bronchialasthma, muscularpain, rheumatism, 
neurological disease 
 
MILAGU 
Botanical Name : Piper nigrum 
English Name : Black pepper 
Family  : Piperaceae 
Organoleptic Character 
Taste   : Bitter, pungent 
Potency  : Hot 
Division  : Pungent 
 
   
 
  
- 
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Actions: 
 Carminative 
 Pungent 
 Antiperiodic 
 Analgesic 
 Anti- inflammatory 
 Antioxidant 
 Cyclo oxygenase inhibitory activity 
 
EXTERNAL DRUG :  VAATHA MEGA NARAYANA ENNAI 
VAAIVIDANGAM 
Botanical Name : Emblicaribes 
English Name : Embelia 
Family  : primulaceae 
Organoleptic Character  
Taste   : Bitter 
Potency  : Hot 
Division  : Pungent 
 
  À¡ñÎÌð¼õ ÌýÁõÀÕóàÄ §¿¡öÅ¡¾ó 
     ¾£ñÎ ¾¢Ã¢Å¢¼ï º¢ÃóÐñ¼õ -âñ¼ÁÊ 
     §¿¡öÅ¢Çí¸ì ¸¡ð¼¡¾ Ññ¸¢ÕÁ¢ Â¡ºÉôÒñ 
Å¡öÅ¢Çí¸í¸¡ð¼Å¢ÕÁ¡÷. 
 
Actions: 
 Carminative 
 Antheilmintic 
 Stimulant. 
 Stomachic. 
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VELLULI 
 
Botanical Name           :  Alluim sativum 
English Name       : Garlic 
Family   : Amaryllidaceae 
 
Organoleptic Character  
Taste    : Pungent 
Potency   : Hot 
Division   : Pungent 
 
ºýÉ¢§Â¡Î Å¡¾ó ¾¨Ä§¿¡× ¾¡û 
ÁýÉ¢ÅÕ ¿£÷ì§¸¡¨Å Åýº£¾õ «ýÉ§Á 
¯ûÙûÇ¢ ¸ñÀ¡öÅýº£¾õ 
¦ÅûÙûÇ¢ ¾ýÉ¡ø ¦ÅÕñÎ. 
 
Actions:  
 Carminative 
 Tonic 
 Alterative 
 Stimulant 
 Expectorant 
 Diuretic 
 Anthelmintic. 
KODIVELI 
Botanical Name :  Plumbago indica 
Family  : Plumbaginaceae  
Used part  :  Root 
Organoleptic Character  
Taste   : Pungent 
Potency  : Hot 
Division  : Pungent 
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¦À¡ÐÌ½õ: 
  ¸ðÊÅ¢Ã½í¸¢Ãó¾¢ ¸¡ø¸û «¨ÃÂ¡ôÒì 
¸ðÊîÝ ¨ÄÅ£ì¸í ¸¡úãÄõ-ÓðÊÃò¾ì 
¸ðÊ¿£ §ÃüÈí ¸Éò¾ ¦ÀÕÅÂ¢Úõ 
«ðÎí ¦¸¡Ê§ÅÄ¢ Â¡õ 
Action:  
 Tonic  
 Stomachic 
 Caustic 
 Anti-pyeritic 
 
SATHA KUPPAI 
Botanical name      :  Anethum graveolens. 
English name        : The dill, Gardendill, Anet. 
Family    : Umblliferae  
Organoleptic Character  
Taste   : Sweet, Pungent 
Potency  : Hot 
Division  : Pungent 
Used parts  :   leaves, flower, seeds. 
¦À¡ÐÌ½õ: 
Å¡¾§Á¡Î Ý¾¢¸¡ Å¡¾õ º¢ÃÍ§¿¡ö 
§Á¡Ð¦ºÅ¢ §¿¡ö¸À§¿¡ö ãÎÍÃõ-µÐ¸¢ýÈ 
ãÄì ¸ÎôÒ Ó¾¢÷À¢Éºõ §À¡Ìõ 
»¡Äî º¾ìÌô¨À ¿¡... 
 
COCONUT OIL 
Botanical name      : Cocus nucifera 
English name          : Coconut palm. 
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Family    : Arecaceae 
Organoleptic Character  
Taste   :   Astringent 
Potency  :   Cold 
Division  : Pungent 
Action: 
 Nutritive. 
 Refrigerant 
 Diuretic 
 Demulcent. 
 
¦À¡ÐÌ½õ: 
§¾í¸¡Â¢ ¦¿öÂ¾É¡ü È£Â¡øÅÕÒñ§À¡õ 
À¡í¸¡¸ì Üó¾ü À¼÷ó§¾Ú ¿£í¸¡¾ 
ÀøÄÊÂ¢ý §É¡Ôõ À¼÷¾¡ Á¨Ãº¢ÃíÌõ 
«øÄÄÈô §À¡¦Áý ÈÈ¢ 
 
ELL ENNAI 
Botanical name :  Sesame indicum 
English name  : Gingelly oil. 
Family  : Pedaliaceae 
Used parts       :  Seed 
Organoleptic Character  
Taste   :   Sweet 
Potency  :   Hot 
Division  :    Sweet  
¦À¡ÐÌ½õ: 
 
Òò¾¢¿Â ¿ìÌÇ¢÷îº¢ âÃ¢ôÒ ¦ÁöôÒÇ¸ï 
ºòÐÅí ¸¡ó¾¢ ¾É¢Â¢û¨Á ¦Áò¾×ñ¼¡í 
¸ñ§½¡ö ¦ºÅ¢§¿¡ö ¸À¡Ç«Æø ¸¡º§¿¡ö 
Òñ§½¡ö§À¡ ¦Áñ¦½öÂ¡ü §À¡üÚ 
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Action:  
 Emmenagogue 
 Stimulant 
 Tonic 
 Diuretic 
 Galactogogue. 
 Laxative. 
 
 
VEPPA ENNAI 
Botanical name      :  Azadiracta indica 
English name       : Neem oil 
Family  : Meliaceae. 
Organoleptic Character  
Taste   :   Bitter 
Potency  :   Hot 
Division                : Pungent  
Used parts         :  Seeds 
Action:  
 Anthelmintic. 
 
AMANAKKU ENNAI      
Botanical name      : Ricinus communis 
English name          : Castor oil 
Family    : Euphorbiaceae. 
Organoleptic Character  
Taste   :  Bitter 
Potency  :   Hot 
Division  : Pungent 
Used parts         :  Seed 
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Action: 
 Emollient. 
 Laxative. 
 
¦À¡ÐÌ½õ: 
 
¬Á½ìÌ ¦¿öÂ¡ ÄÉÄÓñ¼¡ Á¢Â¡Å÷ìÌõ 
¦¸¡ûÇ¢øÅÂ¢ÚÅ¢Îí §¸¡ÃÓûÇÅ¡ÔÅÚõ 
¯ûÇ¢øÅÕ ÌýÁõ§À¡ §Á¡Ð..... 
 
PUNGU ENNAI 
 
Botanical name :  Pongamia pinnata 
Family  : Fabaceae 
Organoleptic Character  
Taste   :   Bitter, Astringent 
Potency  :  Hot 
Division  : Pungent  
Used parts         :  Seed 
¦À¡ÐÌ½õ: 
«í¸ ÁÆ¸¢Îõ¦ÅüÀ¡õÒí¸¢ ¦¿öÉìÌò 
¾í¸õ§À¡ü ¸¡ó¾¢ÂÐ ¾¡Ûñ¼¡ó ¾¢í¸ñÓ¸ 
Á¡§É Å¢ÄÌ¦ÁÉî.... 
Action: 
 Antiseptic. 
 Stimulant 
 
OMAM 
Botanical name  : Carumc opticum 
Family   :  Solanaceae 
Used part   :  Seeds 
Organoleptic characters: 
Taste   :  Pungent 
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Potency  :  Hot 
Division  :  Pungent 
 
 
General properties: 
"º£¾ÍÃí ¸¡ºï ¦ºÃ¢Â¡Áó ¾õ¦À¡ÕÁø 
§À¾¢Â¢¨Ãî ºø¸ÎôÒ §ÀÃ¡Áõ- µ¾¢ÕÁø 
Àø¦Ä¡ÎÀøãÄõ À¸Á¢¨Å§¿¡ ¦Âý¦ºÔ§Á¡? 
¦º¡ø¦Ä¡Î §À¡õ µÁ¦ÁÉî ¦º¡ø." 
- («¸ò¾¢Â÷ Ì½Å¡¸¼õ) 
Chemical Constituents: 
 The chemical composition of essential oil obtained from dry dry fruits of carum.  
Thymol (35-60), a-pinene, p-cymene, limonene and a-terpinene have been found.  
Camphene, carvacrol, dipentene, myrcne, phenols, terpinene, thymine, thymol, linoleic 
acid. 
 
Actions: 
Carminative, Stimulant, Stomachic, Anti spasmodic, Tonic, Antimicrobial, 
Diuretic, Antispasmodic. 
 
Uses: 
A paste of the crushed fruit is applied externally for relieving pains. 
   
PERUNGAYAM 
Botanical name :  Ferula asafoetida 
 Family   :  Umbelliferaceae 
Used parts  :  Gum-Resins 
Organoleptic characters 
 Taste   :  Pungent 
 Potency  :  Hot 
 Division  :  Pungent 
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General properties: 
"¾ó¾§Å ¾ó¾ ãÄò¦¾ØõÀ¢½¢ 
   ºÕÅ¸¡ûõÅ¢Õîº¢¸í¸£¼õÁ¡ 
 Áó¾õÅ¡¾õ ¯¾¡Å÷ò¾õ «øÌø§¿¡ö 
   Á¡÷À½í¸ð¼ ÌýÁõÁ§¸¡¾Ãõ” 
- (§¾¨ÃÂ÷ Ì½Å¡¸¼õ)   
It is used for Gum diseases, snake poisons, scorpion poisons, vaatha diseases,              
ulcer, ascities. 
Chemical constituents: 
 Organic sulphur compound, volatile oil containing essential oil of glic- allyl, 
allylpersulphide and two terpenes, ferulic acid, ester of ssaresino- tannol, alsomail, acetic, 
formic and valerainic acids. 
 
Actions: 
 Stimulant, Carminative, Anti spasmodic, Anthelmintic, Emmengagogue, 
Expectorant, Nervine tonic. 
    
VASAMBU 
Botanical name : Acoruscalamus 
Family  :  Arecacea 
Useful parts  :  Rhizome 
Organoleptic characters 
 Taste  :   Pungent 
 Potency :  Hot 
 Division :  Pungent 
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Actions: 
 Anodyne, Aphrodisiac, Aromaic, Febrifuge, sedative, Stimulant. 
General properties: 
"À¡õÀ¾¢ ¿ïºü Ò¾ôÒñ ÅÄ¢Å¢¼À¡¸í ÌýÁõ 
ÝõÀ¡ Ã¢Ãò¾À¢ò ¾õÓ¸ ¿¡üÈõÅýÝ¨ÄºýÉ¢ 
Å£õÀ¡õ¨À ¸¡ºõ À¢Ä£¸ï º¢Ä¢À¾õ Å£È¢ÕÁø 
 ¾¡õÀ¡í ¸¢ÕÁ¢ Â¢¨Å§ÂÌ Á¡º¢Å ºõÀ¢¨É§Â. 
       - (§¾¨ÃÂ÷ Ì½Å¡¸¼õ)   
Chemical constituents: 
Asarone, Calamenol, Calamene, Eugenol, Methyl, Eufenol, Pinene, Camphene, 
Calamol, Azulene. 
 
Action: 
Stimulant, Stomachic, Antiperiodic Carminative, Nauseant, Emetic, Disinfectant, 
Germicide, Spasmolytic, Hypothermic, Anticonvulsant 
 
Uses: 
 Plant causes sedative effect.  It also reduces pain (Analgesic effect) 
 
Phytochemicals: 
 Glucosideacorin renders the aromatic.  Acorenone, isoshyobunine, b-asarone, 
calamendiol, -selinene, a-calacorene, calamuseneone, camphone and shyobunone are the 
constituents of the essential oil of sweet flag. 
Paal (Milk) 
À¡Ä÷ ¸¢ÆÅ÷ ÀÆïÍÃò§¾¡÷ Òñ½¡Ç¢  
ÝÄÂ¡÷ §Á¸ò§¾¡÷ ÐüÀÄò§¾¡÷ ²ÖÁ¢Å÷ 
±øÄ¡÷ìÌ Á¡Ì Á¢¨Çò¾Å÷ìÌï º¡¾¸Á¡õ 
¿øÄ¡öÀÍÅ¢ýÀ¡ø ¿¡ðÎ. 
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Properties of Milk 
Cow’s milk is useful to children, adults, persons with chronic fever and having 
sores, arthritic complaints, syphilis and weaklings.  
 
Kaadi(viniger) 
 
À¢ò¾ ÁÂì¸ÁÚõ §ÀÃÅ¢„ ¾õÓÈ¢Ôõ 
¯üÈÀ¢½¢ Â¢üº¢Ä¨Å §Â¡Îí¸¡ñ ºüÚõ 
ÅÆí¸¡ Åº£ÃñÓõÅý§À¾¢ Ôõ§À¡õ 
ÀÆí¸¡ÊìÌûÇÀÂý 
 
Properties of vinegar 
Vineger cures giddiness due to bilious affections. It nullifies the effect of 
medicine and cures anorexia and diarrhoea  
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INTERNAL MEDICINE: VAATHA CHOORANAM 
 
 
ATHIMATHURAM      NELLI 
 
   
PARANGIPATTAI     KADUKKAI 
  
    
 DHEVATHARU     CHUKKU 
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 THIPPILI                        THANDRI 
  
 
  MILAGU     KIRAMBUS 
   
 POOLANGILANGU   ATHIVIDAYAM
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EXTERNAL MEDICINE: VATHA MEGA NARAYANA ENNAI 
 
 KODIVELI     MILAGU 
   
 
VASAMBU      VAIVIDANGAM 
   
 
 PERUNGAYAM                                  OOMAM
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  VELLULI     CHUKKU 
   
 
  THIPPILI     KIRAMBU 
   
 
  SATHAKUPPAI   KADUGAROHINI 
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  KAADI                                    NALLENAI
  
 
 
 VEPPAENNAI                           VILAKKENAI
  
 
MILK 
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MATERIALS AND METHODS 
STANDARD OPERATING PROCEDURE: 
Source of raw drugs: 
           The required raw drugs for preparation of “VATHA CHOORANAM”(Internal) 
and “VAATHA MEGA NARAYANA ENNAI” (External) will be purchased from a well 
reputed country shop. These raw drugs will be authenticated by the competent  
Authority of  Medicinal Botany, Then the medicines are purified and prepared in  
Gunapaadam Laboratory of National Institute of Siddha. 
 
INTERNAL MEDICINE:  VAATHA  CHOORANAM 
Ingredients:  
Parangipattai[ RootofSmilax china]   -        l6 kalanju  (80g) 
Athimathuram[ Root of Glycyrrhizaglabra]             -  10 kalanju (50g) 
Kadukkai  [ Fruit of Terminalia chebulla]              - 4 kalanju  (20g) 
 Nellikai  [ Fruit of Phyllanthus emblica]   -  4 kalanju  (20g) 
 Thandrikai  [ FruitTerminalia bellirica]         - 4 kalanju  (20g) 
 Poolangilangu [ Tuber of Kaemifera galanga] -      4 kalanju  (20g) 
 Kirambu [ Bark of Syzygium aromaticum]  -    4 kalanju  (20g) 
 Dhevatharam [ Wood of Cedrus deodra]  -  4  kalanju (20g) 
Athividayam [ Root of Aconitum heterophyllam] - 4  kalanju (20g) 
 Chukku [ Tuber of  Gingiber officinale]  - 4 kalanju  (20g) 
 Milagu [ Fruit of Piper nigrum]   - 4 kalanju  (20g) 
Thippili[ Fruit of Piper longum]    - 4 kalanju  (20g) 
 
Purification of raw drugs: 
Purification of Parangipattai: 
It is dried and then powdered and boiled in the steam of milk(pittaviyal) 
[ Ref:      Sarakugalinsutheemuraigal  page  :11]    
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Purification of Chukku: 
Soak   in  lime  stone  water  for  a period  of   time and dry  it  in  shade  then  
peel off the outer layer.  
 [Ref: Sarakugalinsutheemuraigalpg .6] 
Purification of Milagu: 
Soak   in  butter  milk  for  a  period  of 1 saamam (3 hours)  then  allow  it  to  
dry. 
 [Ref: SikichaRathinaDeepamEnnumVaithiyaNool  page  28] 
Purification  of  Thippili: 
 Soak   in  juice  of  Lime  for  a  period  of time   then  allow   it  to  dry.   
 [Ref: Sarakugalinsutheemuraigal  page  7] 
Purification of Kadukkai 
Remove the nut and use the outer covering of the drug   
                     [Ref: Sarakugalinsutheemuraigal  Page  :4] 
Purification of Nellimulli: 
Remove the nut and use the outer covering of the drug   
[ Ref:  Sarakugalinsutheemuraigal  page  :9]                                                                                                                                     
Purification of Thandrikai: 
Remove the nut and use the outer covering of the drug 
 [Ref: Sarakugalinsutheemuraigal  page  7] 
Purification of Athimathuram: 
Clean in pure water then remove the outer covering and cut into small pieces 
and then dry it 
Purification of Elavangam:                         
 Dry it in sunlight and fry  
                      [Ref: Sarakugalinsutheemuraigal  page  :6] 
METHOD OF PREPARATION  
All the above raw drugs are purified,   were pulverized and sieved by a cloth 
and stored in a clean container   
EXTERNAL MEDICINE-:VAATHA MEGA NAARAYANA ENNAI 
Ingredients: 
Punguennai[ Oil of Pongamiapinnata]   -   5 palam(17.5g) 
Veappaennai[Oil of Azadiractaindica]      -    5 palam(17.5g) 
MATERIALS AND METHODS 
 
 Page 46 
 
Vilakkennai[Oil of Ricinuscommunis]   - 5 palam(17.5g) 
Nallennai[Oil of Sesamumindicum]       -           5 palam(17.5g) 
Milk       -           ¼ padi (325ml) 
Kaadi[Vinegar].      -           ½ padi (650ml)                 
Kodiveli[ Root of Plumbago indigo]   -           5 palam(17.5g) 
Milagu[Fruit of Piper nigrum]   - 5 palam(17.5g) 
Vasambu[Rhizome of Acoruscalamus]  - 5 palam(17.5g) 
Kadugarohini Root of  Picrorhizascrophulariflora]  -           5 palam(17.5g) 
Porithakaayam[Resin of Ferullaasafetida]             -        5 palam(17.5g) 
Sathakuppai[Anethumgraveolens]                           -           5 palam(17.5g 
Chukku[ Rhizome of Zingiberofficinale]              -           5 palam(17.5g 
Thippili[ Fruit of  Piper longum]                       -   5 palam(17.5g 
Velulli[ Bulb of Allium sativum]                         - 5palam(17.5g 
Kirambu[ Flower of Syzygiumaromaticum]         - 5palam(17.5g 
           .Oomam[ Seed of Trachyspermumammi]             -           5palam(17.5g 
Vaividangam[Seed of Embeliariben ]                        -           5palam(17.5g 
Preparation:   
The purified raw drugs were dried, pulvarised by kalvam and made into karam 
by adding Kaadithen  mixed with oil and then boiled till it attained the suitable 
consistency. 
Drug storage: 
The trial drug vatha chooranam is stored in a glass jar and vaatha mega 
naarayana ennai is stored in clean and dry narrow mouthed bottles. 
 
Dispensing:  
The drug vatha chooranam is given in powder form in packets   and vaatha 
mega naarayana ennai is given in plastic bottles. 
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PRECLINICAL STUDY 
CHEMICAL EVALUATION 
  Experimental procedure:  
       5 g of Vaatha Chooranam was taken in a 250 ml of clean beaker and 50ml of 
distilled water was added to it. Then it was boiled well for about 10 min. Then it is 
allowed to cool and filtered in a 100 ml volumetric flask and made up to 100 ml 
with distilled water. This preparation is used for the qualitative analysis of acidic/ 
basic radicals and biochemical constituents in it. 
Preparation of extract:  
5gm of Vaatha Chooranam is weighed accurately and placed in a 250ml clean 
beaker and 50ml of distilled water was added with it. Then it was boiled well for 
about 10 minutes. Then it was allowed to cool and filtered in a 100ml volumetric 
flask and made up to 100ml with distilled water. The bio-chemical analysis of 
Vaatha Chooranam was done at Biochemistry lab, National Institute of siddha, 
Chennai-47. 
Preliminary test for Copper, Sodium, Silicate and Carbonate: 
 Test for Silicate: 
a. A little (500mg) of the sample is shaken well with distilled water. 
b. A little(500mg) of the sample is shaken well with con. HCl/Con. H2So4. 
 Action of Heat: A small amount (500mg) of the sample is taken in a dry test 
tube and heated gently at first and then strong. 
 Action of Heat: A small amount (500mg) of the sample is taken in a dry test 
tube and heated gently at first and then strong. 
 Flame Test: A small amount (500mg) of the sample is made into a paste 
with con. HCl in a watch glass and introduced into non-luminous part of the 
Bunsen flame. 
 Ash Test: A filter paper is soaked into a mixture of sample and dil. cobalt 
nitrate solution and introduced into the Bunsen flame and ignited. 
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Test For Acid Radicals 
 Test For Sulphate:2ml of the above prepared extract was taken in a test 
tube and 2ml of 4% dil. ammonium oxalate solution was added. 
 Test For Chloride: 2ml of the above prepared extracts was added with 2ml 
of dil-HNO3 until the effervescence ceases off. Then 2 ml of silver nitrate 
solution was added. 
 Test For Phosphate: 2ml of the extract was treated with 2ml of con.HNo3 
and 2ml of dil. ammonium molybdate solution.   
 Test For Carbonate: 2ml of the extract was treated with 2ml dil. 
magnesium sulphate solution 
 Test For Nitrate:1gm of the substance was heated with copper turning and 
concentrated H2SO4 and viewed the test tube vertically down. 
 Test For Sulphide: 1gm of the substance was treated with 2ml of con. HCL 
 Test For Fluoride & Oxalate: 2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil. calcium chloride solution and heated. 
 Test For Nitrite: 3drops of the extract was placed on a filter paper, on that-2 
drops of dil. acetic acid and 2 drops of dil. Benzidine solution were placed. 
Test For Basic Radicals 
 Test For Lead: 2ml of the extract was added with 2ml of dil. potassium 
iodine solution. 
 Test For Copper: One pinch (50mg) of substance was made into paste with 
con. HCl in a watch glass and introduced into the non-luminous part of the 
flame. 
 Test For Aluminium: In the 2ml of extract dil. sodium hydroxide was added 
in 5 drops to excess. 
 Test For Iron: 
a.To the 2ml of extract add 2ml of dil. ammonium solution 
b. To the 2ml of extract 2ml  thiocyanate solution and 2ml  of con HNo3 is 
added 
 Test For Zinc: In 2ml of the extract dil.sodium hydroxide solution was 
added in 5 drops to excess and dil.ammonium chloride was added.  
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 Test For Calcium: 2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution  
 Test For Magnesium: In 2ml of extract dil.sodium hydroxide solution was 
added in drops toexcess. 
 Test For Ammonium:In 2ml of extract 1 ml of Nessler's reagent and excess 
of dil. sodium hydroxide solution were added. 
 Test For Potassium:A pinch (25mg) of substance  was treated  with 2ml of 
dil. sodium nitrite solution and then treated with 2ml of dil. cobalt nitrate in 
30% dil. glacial acetic acid. 
 Test For Sodium: 2 pinches (50mg) of the substance was made into paste 
by using HCl and introduced into the blue flame of Bunsen burner. 
 Test For Mercury: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution.  
 Test For Arsenic: 2ml of the extract was treated with 2ml of dil. sodium 
hydroxide solution. 
Other constituents 
 Test For Starch : 2ml of extract was treated with weak dil. iodine solution  
 Test For Reducing Sugar: 5ml of Benedict's qualitative solution was taken in 
a test tube and allowed to boil for 2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes.  
 Test For The Alkaloids: 
a) 2ml  of the extract is treated with 2ml of dil. potassium iodide solution.    
b) 2ml of the extract is treated with 2ml of dil.picric acid. 
 Test For Tannic Acid: 2ml of extract was treated with 2ml of dil. ferric 
chloride solution 
 Test For Unsaturated Compound: In the 2ml of extract 2ml of dil. 
Potassium permanganate solution was added.  
 Test For Amino Acid: 2 drops of the extract was placed on a filter paper 
and dried well, and then 20ml of Burette reagent was added in it. 
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TOXICITY STUDIES OF VAATHA CHOORANAM 
To evaluate the safety profile of Vaatha chooranam short term and long term 
toxicity study carried out as followed. The principles of laboratory animal care were 
followed and the Institutional Animal Ethical Committee approved the use of 
animals and the study design. IAEC registered and approval number:  
(IAEC).(NIS/IAEC/III/05/29092016dated29.09.2016) for Short term toxicity study 
and Long term toxicity study 
 
Experimental Animals: 
Species               : Wistar albino Rats 
Sex      : Male and Female  
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with bedding with    
Husk 
 
Husbandry    : 12-h light/12-h dark cycle/ Room  
Temperature 22°C±3°C and relative  
Humidity30–70% 
Feed and Water   :  Rodent pelleted feed RO purified water   
Ad libitum   
Identification   : Animals will be kept in Polypropylene   
Cages and numbered 
Experimentation Details of Short term Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : WHO 
Length of exposure to test substance : 1 day 
No of Animals    : 5 Female+ 5 Male / group 
Control group    : Vehicle (honey) 
Test groups    :  Vaatha Chooranam2000 mg/kg.b.wt 
 
The wistar albino rats of both sex weighing 150-200g will be obtained from 
authorized animal breeders of animal laboratory in TANUVAS, Madavaram, Chennai 
MATERIALS AND METHODS 
 
 Page 51 
 
and stocked in animal house at National Institute of Siddha, Chennai.  Animals will be 
house in cage at 22°C±3°C andrelative humidity 30–70% and have free access to 
standard rat pellet diet (Sai Meera Foods Pvt. Ltd., Bangalore). The animals will be 
dosed with Vaatha chooranam by oral for one day and monitored for behavioural 
parameters for the first 4 hours after drug administration. Body weight of the animal 
will be monitored at weekly intervals. The animals that the die within this period will 
be subjected to necropsy. Remaining animals will be weighed and sacrificed under  
the injection of Pentathal Sodium on the 15
th
day of the Study period. The 
toxicological effect was assessed on the basis of mortality.  
Preparation of Test Drug Doses: 
Groups No. of Rat 
Group I:  Vehicle control (honey) 10 (5M+5F) 
Group II: test drug (VC)- 2000 mg/kg b.wt 10 (5M+5F) 
                 *VC- Vaatha chooranam 
Route of administration 
Oral route were selected because it is the normal route of clinical administration. 
Administration of Dose 
The animals were kept in fasting (only food was with held) for 12 hrs and 
weighed prior to dosing. Three animals were used for each step. A single dose of the 
solution (2000mg/kg) was consecutively administered by oral gavage using 
intubation cannula. Food was with held for another 4 hrs after dosing and 
administration of drug. As per the guide line the starting dose level was taken as 
2000mg/kg body weight. 
Observations: 
Observations were made and recorded systematically and continuously 
observed after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hour, 4 hour and up to 24 hours observation 
 All rats will be observed twice daily on week days for 14 days 
 Body weight per weekly one times 
 Feed intake per day 
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Cage side observation  
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality 
Necropsy: 
Necropsy includes gross examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye,  lungs, 
heart, spleen, liver, kidneys, adrenals, uterus, of all animals. 
Experimentation Details of Long term Toxicity Study: 
Experimental Animals: 
Species               : Wistar Albino Rats 
Sex      : Male and Female 
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    : Polypropylene cages with bedding with   
        Husk 
Husbandry    : 12-h light/12-h dark cycle/ 
       Room temperature 22°C±3°C and 
       Relative humidity 30–70% 
Feed and Water   : Rodent pelleted feed 
       RO purified water ad libitum 
Identification   : Animals will be kept in 
       Polypropylene cages and 
       Numbered 
Experimentation Details of Long Term Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : WHO 
Length of exposure to test substance : 90 days 
No of Animals    : 10 Female+10 Male / group 
Control group    : Vehicle (honey) 
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Test groups    : Vaatha Chooranam (Low dose, Mid dose,               
                                                                        High dose)                                                  
The 80 Wistar albino rats of both sex selected randomly. The animals were 
divided into four groups. Each groups consist at 20 animals. First group treated as 
vehicle control and second, third and fourth groups were treated with Vaatha 
chooranam Low dose (360 mg), Mid dose (900 mg) and High dose (1800 mg) 
respectively. The animals were dosed with Vaatha chooranam by oral for 90 days and 
are monitored for behavioural parameters for the first 4 hours after drug 
administration. Body weight of the animal was be monitored at weekly intervals. The 
animals that die within this period was be subjected to necropsy. Remaining animals 
was be weighed and sacrificed under the injection of Pentathal Sodium on the on 
the91
st day
 of the study. Blood will be collected from the anesthetized animals from 
abdominal aorta. and the following investigations like Haematology, Biochemical 
analysis and Histopathology are done. 
 
They above dose were fixed from the result of Long term toxicity study 
Groups No. of Rats 
Group I:  Vehicle control (honey) 20(10M+10F) 
GroupII:Test drug (VC)- low dose (360mg/kg b.wt) 20(10M + 10F) 
GroupIII: Test drug(VC) - Mid dose (900mg/kg.b.wt) 20(10M +10F) 
GroupIV:Test drug(VC) High dose (1800 mg/kg b.wt) 20(10M +10F) 
 
*VC- Vaatha chooranam 
Preparation and administration of dose: 
Vaatha Chooranam was d i s s o l v ed  i n  honey t o  obtain concentrations of 
1800mg/ml. It was administered to animals at the dose levels of 360mg/kg b.wt, 
900mg/kg b.wt and 1800mg/kg b.wt. The test substance solutions were freshly 
prepared every two days once for 90days. The control animals were administered with 
honey as vehicle. Administration was given by oral, once daily for 90 consecutive 
days.  
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Observations: 
Experimental animals were kept under observation through out the course of 
study For the following 
 All rats will be observed twice daily on week days for 90 days 
 Body weight per weekly one times 
 Feed intake per day 
Cage side observation   
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, pilo erection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality. 
Gross necropsy: 
Gross necropsy includes examinations of the external surface of the body, all 
orifices, cranial, thoracic and abdominal cavities and their contents. Brain, eye, lungs, 
heart, spleen, liver, kidneys, adrenals, uterus, of all animals. 
Laboratory Investigations: 
On the 91
st 
day, the animals were fasted over night, then anesthetized to 
collect blood samples from the abdominal aorta in two tubes: one with  EDTA for 
hematological parameters, another one without any anticoagulant and was centrifuged 
at 4000 rpm at 4°C for10 minutes to obtain the serum for biochemical parameters. 
Hematological Investigations: 
Blood samples of control and experimental rats were analyzed for hemoglobin 
(Hb), total red blood corpuscles (RBC), white blood corpuscles (WBC) count,  Mean 
corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH) were calculated. 
Biochemical Investigations: 
Serum samples of control and experimental rats were analysed for Bilirubin, 
Uric Acid, Creatinine, Triglyceride, Total Cholesterol, HDL, LDL, VLDL, using 
standard methods. Activities of glutamate oxaloacetate transaminase/Aspartate amino 
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transferase (GOT/AST) and glutamate pyruvate transaminase/ Alanine amino 
transferase (GPT/ALT) were estimated as per the colorimetric procedure. 
Necropsy: 
All the animals were sacrificed on the 91
st 
day. Necropsy of all animals was 
carried out and the weights of the organs including liver, kidneys, spleen, brain, heart, 
lungs and stomach were recorded. 
Histopathology: 
The organs included liver, kidneys, spleen, brain, heart, lungs and stomach of 
the animals were preserved, and they were subjected to histopathological 
examination. 
Histopathological investigation of the vital organs was done. The organ pieces 
(3-5µmthick) of the three different (low, mid, high) dose level was preserved and was 
fixed in 10% formalin for 24 hand was hed in running water. Samples were 
dehydrated in an auto technic on and then cleared in benzene to remove absolute 
alcohol. Embedding was done by passing the cleared samples through three cups 
containing molten paraffin at 50
o
C and then in a cubical block of paraffin made by the 
“L” molds. It was followed by micro to me and the slides were stained with 
Haematoxylin-eosin. 
CLINICAL STUDY 
STUDY TYPE                            
An open clinical trial 
STUDY PLACE                             
OPD & IPD of Ayothidass pandithar, hospital, 
National Institute of Siddha, Chennai-47 
STUDY PERIOD                        
             18 months 
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SAMPLE SIZE                           
              40 patients (Both in IPD and OPD ) 
SUBJECT SELECTION: 
  Patients reporting with symptoms of Vali Azhal Keel Vayu will be subjected to 
screening by screening Profoma. After screening they will be enrolled for the study 
fulfilling the inclusion criteria as said below: 
INCLUSION CRITERIA:  
 Age: 18- 60 years. 
 Sex: Both male and female 
 Any of the following three symptoms 
a. Pain and swelling in three are more joint 
b. Morning Stiffness 
c. Rheumatoid factor positive 
d. Deformities like Swan neck and Button hole  
e. Rheumatoid nodules 
f. Symmetrical joints involvement  
 Patient willing to undergo Radiological investigation and for laboratory 
investigation.  
 Patient willing to sign the informed consent.  
EXCLUSION CRITERIA: 
 Pregnancy and lactation 
 Tubercular arthritis 
 Gouty arthritis 
 Diabetic Mellitus 
 Malignant Hypertension 
 Any other  systemic illness 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug 
trial. 
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 Poor patient compliance and defaulters. 
 Patient turning unwilling to continue in the course of clinical trial. 
 Occurrence of any other systemic illness 
TESTS AND ASSESMENTS 
A. Clinical assessment  
B. Siddha investigation 
C. Laboratory investigations 
D. Radiological investigation  
CLINICAL ASSESMENT 
 Arthritis involving three or more joints 
 Symmetrical joint involvement  
 Morning stiffness 
 Spindle shaped appearance of fingers 
 Rheumatoid nodules 
 Swelling of small joints of hands and foot. 
 Swan neck deformity 
B. SIDDHA SYSTEM EXAMINATION: 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
              8.  Moothiram 
a. Neer kuri: 
b. Nei Kuri: 
C. ROUTINE INVESTIGATIONS 
BLOOD 
Hb 
Total WBC Count 
DC- 
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            1.  Polymorphs 
2. Lymphocytes  
3. Eosinophils 
                  4.   Monocytes  
                  5.   Basophils  
Total RBC count  
ESR   ½ Hr:              1 Hr : 
Blood sugar  Fasting :           PP : 
Serum cholesterol 
URINE 
Albumin 
            Sugar (F)          (PP) 
  Deposits 
RENAL FUNCTION TESTS 
            Blood Urea 
Serum creatinine 
LIVER FUNCTION TESTS 
              Serum Total bilirubin 
              Direct bilirubin 
              Indirect bilirubin 
              Serum Alkaline phosphatases 
              SGOT 
              SGPT 
C. SPECIFIC INVESTIGATIONS 
              CRP,  
               RA factor,  
               ASO Titre, 
               Uric acid 
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DATA COLLECTION FORMS: 
Required information will be collected from each patient by using following 
forms. 
 
FORM I :     Screening and Selection Proforma  
FORM II :     History Taking Proforma 
FORM III :    Laboratory Investigation form 
FORM IV :  Consent Form 
FORM V :     Withdrawal Form and Pharmacovigilance Form 
FORM Vl :  Compliance form 
FORM VII : Patient Information Sheet  
FORM VIII :  Dietary Advice form 
 
STUDY ENROLLMENT 
Patients reporting at the OPD of NIS with the clinical symptoms of VALI 
AZHAL KEEL VAYU will be examined clinically. Based on the inclusion and 
exclusion criteria, they will be enrolled for the study. 
The patients who are going to be enrolled would be informed about the study, 
trial drug, possible outcomes and the objectives of the study in their vernacular 
language. After ascertaining the patient’s willingness, informed consent would be 
obtained in written form. 
All these patients will be given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone number 
etc. will be given, so as to report easily should any complications arise. 
Complete clinical history, complaints and duration, examination findings and 
laboratory findings would be recorded in the prescribed Proformas. Patients would be 
advised to take the trial drug and appropriate dietary advice. 
CONDUCT OF THE STUDY: 
Purgation with Meganatha kulikai– 2 od with hot water in empty stomach at 
early morning with Hot Water will be given for balancing the deranged Mukuttram on 
the first day of the treatment.  
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The next day onwards the trial drug Vatha chooranam (Internal) and Vaatha 
Mega Naarayana Ennai (External) is given for 48 days. OPD patients are asked to 
visit the hospital once in 7 days. At each clinical visit clinical assessment is done and 
prognosis will be noted. For IPD patients the clinical assessment will be done daily 
with the supervision of the faculty member in the Ward. 20 patients in IP ward with 
the trial medicines. The results will be compared at the end of the study. Laboratory 
investigations and radiological investigation are done on the first day and 49
th 
day of 
the trial. At the end of the treatment, the patients will be advised to visit the OPD for 
follow-up for futher 2 months for observing any recurrence. Defaulters will not be 
allowed to continue and be withdrawn from the study. 
DATA ANALYSIS:  
After enrolling the patient in the study, a separate file will be maintained for 
each and every patient and all forms and other information will be kept in the file. The 
screening forms will be filed separately. The data entry will be monitored by the Head 
of the department and faculties of the concerned department. All collected datas will 
be statistically analysed by Senior Research Officer (Statistics) for logical errors and 
incompleteness of data to avoid any bias. No modification in the results is permitted 
for unbiased reports. Then final report will be generated 
ADVERSE EFFECTS/SERIOUS EFFECTS MANAGEMENT: 
In this Study No Adverse Reactions Were observed during the course of 
treatment 
OUT COME OF THE RESULT. 
The outcome of the result is assessed by universal pain scale and restricted 
movement scale before and after treatment. Rheumatoid Arthritis Patients are  
included for the study based on  EULAR SCALE Criteria  
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OUTCOME 
i. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
0    :    No Pain 
1-3 :  Mild pain 
4-6 :   Moderate pain 
7-10 :    Severe pain 
 
ii. RESTRICTED MOVEMENT ASSESSMENT SCALE:GRADATION OF 
MOVEMENTS 
Grade 1  –  Able to perform normal duties 
Grade II  –  Moderate Restriction – Self-care is possible 
Grade III  –  Marked restriction – Limited self-care /some assistance  
Required. 
Grade IV  –  Confined to bed or wheel chair 
 (Ref: Clinical manual for nursing practice (National Institute of Health 
Warren Grant Magnuson Clinical Centre) 
 
Rheumatoid Patients are Assessed for the study based on EULAR SCALE Criteria  
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iii. EUROPEAN LEAGUE AGAINST RHEUMATISM CLASSSIFICATION 
CRITERIA FOR RHEUMATOID ARTHRITIS 
Classification criteria for RA (Add score of categories A-D;A Score of > 
or=6/10 is needed for classification of a patient as having definite RA 
     A .Joint involvement 
          1 large joints                                                                                          0 
          2-10 large joints                                                                                        1 
          1-3 small joints (with or without involvement of large joints)                 2 
          4-10 small joints (with or without involvement of large joints)                  3 
>10 joints (at least 1 small joint)                                                          5 
  B. Serology (at least 1 test  result is needed for classification) 
           Negative RF and negative ACPA                                                         0 
            Low-positive RF or low positive                                                         2 
             High-positive RF or high-positive ACPA                                            3   
   C. Acute –phase reactants (at least 1 test result is needed for classification 
              Normal CRP and normal ESR                                                            0 
               Abnormal CRP or abnormal ESR                                                      1 
A. Duration of symptoms 
<6 weeks                                                                                              0 
≥6weeks                                                                                                 1 
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QUALITATIVE ANALYSIS 
PHYSICO-CHEMICAL ANALYSIS 
 
Table-1: Colour, nature  of  Vaatha Chooranam 
 
 
Table-2: Test for Basic radicals 
S.no Procedures Vaatha Chooranam 
1. Test for Ammonium - 
2. Test for Sodium - 
3. Test for Magnesium - 
4. Test for Aluminium - 
5. Test for Potassium + 
6. Test for Calcium - 
7. Test for Ferrous iron + =+ 
8. Test for Copper - 
9. Test for Zinc - 
10. Test for Arsenic - 
11. Test for Mercury - 
12. Test for Lead - 
 
Inference 
Bio-chemical analysis for basic radicals reveals that Vaatha Chooranam 
contains Potassium, and Iron. 
 
  
S.no Parameters Results Method of Testing 
1. Colour Yellowish green By visual 
2. Odour Odour(Omam Smell) Olfactory examination 
3. Solublity Completely soluble Qualitative 
4. Nature Powder By visual 
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Table-3: Test for Acidic radicals 
S.no Procedures Vaatha chooranam 
1. Test for Sulphate - 
2. Test for Chloride + 
3. Test for Phosphate + 
4. Test for Flouride & Oxalate - 
5. Test for Nitrate _ 
 
Table-4: Test for Acidic radicals 
S.no Procedures Vaatha Chooranam 
1. Test for Starch - 
2. Test for Reducing sugar - 
3. Test for Alkaloids + 
4. Test for Amino acids _ 
5. Test for Tannic acids + 
6. Test for type of compounds                    No Change 
 
Inference 
 Bio-chemical analysis for acid radicals reveals that Vaatha Chooranam 
contains Chloride, phosphate, Alkaloids, Tannic acids 
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Toxicity study Results of Vaatha Chooranam 
Dose finding experiment and its behavioural Signs of Toxicity 
No Dose 
Mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 
 
 
1. Control + - - + + + - - - - - - - - - - - - + - 
 
2. 2000 + - - + + + - - - - - - - - - - - - + - 
 
 
1.Aletness 2.Aggressiveness 3.pilo erection 4.Grooming 5.Gripping 6.Touch 
Response 7. Motor Activity  8. Tremors  9.Convulsions 10.Muscle Spasm 
11.Catatonia 12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhoea 18.Writhing 19. Respiration  20.Mortality 
+ Presence of Activity  
- Absence of Activity 
All the data were summarized in the form of table revealed no abnormal signs 
and behavioural changes in rats at the dose of 2000 mg/kg body weight administered 
orally 
Short term  Toxicity study 
In short term toxicity study, the test drug at Vaatha  Chooranam for single 
dose(2000mg/kg b.wt) was administered. 
There was no mortality or signs of toxicity observed after dosing Vaatha 
Chooranam  2000mg/kg body weight during the study period of 14 days. This indicate 
that the LD50 of Vaatha Chooranam is more then 2000mg/kg b.wt. 
There was no changes in skin and fur, eyes and mucous membranes of all 
animals.  The eating ,drinking habit, sleep pattern, locomotion were normal in all 
animals and no changes in body weight as compared to control group. 
At the end of the 14 
th
 day necropsy was done and there was no abnormality 
seen in test groups as compared to control group during the examination. 
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Food (g/day) intake of albino rats exposed to Vaatha Chooranam 
 
Dose 
(mg/kg/day) 
Control LD MD HD 
1
st
 day 5.54±0.21 6.11±0.21 5.59±0.25 6.2±0.15 
15 
th
 day 6.3±0.18 6.4±0.21 6.7±0.27 7.27±0.27 
30 
th
 day 6.7±0.27 7.07±0.17 6.65±0.18 7.45±0.24 
45 
th
 day 7.07±0.17 7.08±0.18 7.07±0.17 7.45±0.25 
60 
th
 day 7.07±0.17 7.27±0.27 7.37±0.24 7.45±0.25 
75 
th
 day 7.27±0.27 7.37±0.24 7.60±0.28 7.63±0.25 
90 
th
 day 7.60±0.28 7.63±0.25 7.95±0.11 7.75±0.13 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Water (ml/day) intake of albino rats exposed to Vaatha Chooranam 
Dose 
(mg/kg/day) 
 
Control LD MD HD 
1st day 
(ml/rat) 
9.15±0.13 8.13±0.12 9.15±0.12 9.20±0.15 
15 th day 
(ml/rat) 
9.52±0.21 8.13±0.12 8.13±0.12 8.13±0.12 
30 th day 
(ml/rat) 
8.13±0.12 8.13±0.12 9.52±0.21 8.13±0.12 
45 th day 
(ml/rat) 
9.96±0.11 9.25±0.17 9.15±0.12 8.13±0.12 
60 th day 
(ml/rat) 
9.96±0.11 9.52±0.21 9.96±0.11 9.52±0.21 
75 th day 
(ml/rat) 
9.96±0.11 9.96±0.11 10.30±0.13 9.96±0.11 
90 th day 
(ml/rat) 
9.96±0.11 10.30±0.13 9.96±0.11 
9.96±0.11 
 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Body weight (g) changes of albino rats (female) exposed to Vaatha 
Chooranam 
Dose 
(mg/kg/day) 
Control LD MD HD 
1st day 134.16±4.21 138.12±3.50 140.2±2.13 138.14±2.46 
15 th day 164.16±4.21 158.45±2.16 162.36±5.07 157.25±1.67 
30 th day 190.83±6.14 189.16±6.23 192.12±4.21 189.25±5.26 
45 th day 209.16±5.07 206±4.21 210.2±6.30 207±3.16 
60 th day 235.83±4.21 237.38±6.14 240.24±6.14 239.68±4.21 
75 th day 270.83±6.30 272.5±5.02 278.8±2.36 276.26±6.24 
90 th day 315.5±6.44 318.24±6.12 320.6±5.07 318.28±1.36 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Body weight (g) changes of albino rats (male) exposed to Vaatha 
Chooranam 
Dose 
(mg/kg/day) 
 
 
Control 
 
    LD 
 
    MD 
 
      HD 
1st day 139.33±4.13 142.24±4.12 152.16±2.45 148.16±6.27 
15 th day 173±5.79 174.12±5.26 178.16±5.79 176±5.12 
30 th day 203±5.79 204.16±4.23 202.18±9.12 206.33±2.4 
45 th day 236.16±9.24 239±9.24 239.23±8.28 240.25±9.24 
60 th day 288.66±9.24 292.25±6.23 297.26±5.20 296.67±2.67 
75 th day 319.5±8.50 320.1±9.28 326.5±4.13 324.13±4.12 
90 th day 
359.5±9.71 
 
352.18±6.58 348.16±7.02 347.4±8.50 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Histopathology of Uterus  
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Histopathology Analysis Report 
Group ID: C1HFH 
Brain 
 Regular marginal alignment on the neurons with promising histology were 
observed 
 Morphology of neurons in CA1, CA2 and CA3 zones are normal 
Lung 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis 
 Pneuomocyte and capillary appears normal 
 Alveolar sac and septa appears normal with signs of degeneration 
 Pleura and brochioles appears normal 
 Pulmonary vessels and bronchioles appears normal 
Heart 
 Myocardial cells appears normal with well-defined mycoplasma and prominent 
nucleus and nucleolus 
Stomach 
 Lamina propria appears normal with no evidence of infiltration and inflammation 
 Mucosal wall appears normal with regular arrangement of connective tissue 
Liver 
 Cytoplasm appears normal with widen portal tract 
 The centrilobular hepatocytes appears normal with stained cytoplasm 
 Mild congestion of blood vessels were been observed  
Kidney 
 Glomerular cell integrity, basement membrane and nephrotic bundle appears 
normal 
 No signs of lesion or inflammation were observed 
 Proximal and distal convoluted tubule appears normal 
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Spleen 
 No signs of perivascular inflammation 
 Appearance of splenic sinuses, Splenic cord and endothelial orientation was normal 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was 
normal with no significant signs of enlargement 
Uterus 
 Arrangement of stratum basale, functionale and surface epithelium seems normal 
Ovary 
 
 Sequential arrangement of granulosa cells arounds oocyte was normal and regular 
 Follicular cells, cytoplasm and nucleus appears normal 
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Histopathology Analysis Report 
Group ID: C1HMH 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
Lung 
 Bronchial opening appears regular with no signs of infiltration 
 Appearance of alveolar network was normal 
 Nucleus of type I and II alveolar cells looks normal  
Heart 
 No evidence on accumulation of adipose tissue on interstitium 
 No evidence of atherosclerosis and thrombosis 
Stomach 
 Gastric glands, gastric glands including secretary sheath appears normal 
 Normal gastric mucosa containing intact gastric gland cells, parietal cells which are 
spherical cell with deeply stained dark nucleus 
Liver 
 The walls of the lumen appears normal with no evidence of ischemicchanges . 
 No evidence of infiltration 
 Rare appearance of Kupffer cells with no evidence of phagocytosis in intracytoplasmic 
region 
Kidney 
 Interstitial connective tissue appears cohesive with distinct space in between 
 Glomeruli appear widen with prominent space at capsular junction 
 Proximal and distal convoluted tubule appears normal 
 No signs of cellular necrosis  
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Spleen 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was normal 
with no significant signs of enlargement 
 No signs of immunological activities 
Testes 
 Presence of mature somatic cells project the perfect histomorphology of testicular cells 
were observed. Primary spermatocytes with large centered nucleus and dense chromatin 
were observed 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells and 
spermatogonia were normal 
 
 
 
  
OBSERVATION AND RESULT 
 
 Page 91 
 
Histopathology of Brain  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 92 
 
Histopathology of Heart  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 93 
 
Histopathology of Lung  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 94 
 
Histopathology of Stomach  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
 
OBSERVATION AND RESULT 
 
 Page 95 
 
Histopathology of Liver  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
 
OBSERVATION AND RESULT 
 
 Page 96 
 
Histopathology of Kidney  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 97 
 
Histopathology of Spleen  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 98 
 
Histopathology of Uterus  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
 
OBSERVATION AND RESULT 
 
 Page 99 
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Histopathology Analysis Report 
Group ID: C1LFH 
Brain 
Arrangement of the neurons appears intact with no sings of degeneration or apoptotic changes in 
both the samples 
Cortex region showed normal neurons with polygonal to round cell bodies containing dense 
cytoplasm. 
Heart 
Appearance of myocyte was normal 
Endocardium appears normal with no evidence of necrosis 
Fibres appears normal elongated and rod shaped 
Lung 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no sings of 
pulmonary edema 
Stomach 
 Regular arrangement of muscularisexterna and outer longitudinal muscle were observed 
 Regular histology of Inner circular muscle (ICM), gastric pit (GP), and muscularis 
mucosae (MM) were observed 
Liver 
• Diffused vacuolar changes were observed in the mid zonal region 
• Mild congestion on central vein was observed 
Kidney 
 Glomerular appears slightly dilated  
 No signs of lesion or inflammation were observed 
 Proximal and distal convoluted tubule appears normal 
 Interstitial connective tissue of both the sample appear normal 
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Spleen 
 Appearance of central artery and marginal sinus are normal  
 No abnormalities found in lymph node of both the samples 
Uterus 
 Arrangement of stratum basale, functionale and surface epithelium seems normal 
Ovary 
 Appearance of antral follicle, primary oocyte and secondary follicles are normal 
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Histopathology Analysis Report 
Group ID: C1LMH 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
Lung 
 Perivascular region appears normal, Alveolar septa and wall appeared widen and normal 
 No signs of lymphocyte cuffing 
Heart 
o Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei of 
muscle fibers appear oval arrangement 
Stomach 
 Gastric glands, gastric glands including secretary sheath appears normal 
 Normal gastric mucosa containing intact gastric gland cells, parietal cells which are 
spherical cell with deeply stained dark nucleus 
Liver 
 Centrilobular zone appears normal with stable network of hepatocytes 
 The walls of the lumen appears normal with no evidence of  ischemic changes . 
 No evidence of infiltration 
 
Kidney 
 Variable tubular congestion were observed 
 Proximal and distal convoluted tubule appears normal 
 No signs of cellular necrosis  
 
Spleen 
 Marginal sinus (MS) of the rat and its sinus lining cells appears normal 
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the samples. No 
abnormalities found in lymph node of both the samples 
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TESTES 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells and 
spermatogonia were normal 
 No signs of interstitial fibrosis were observed  
 Sperm oriented towards the center of sertoli cells with cluster of tail projected outside was 
observed 
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o Histopathology Analysis Report 
Group ID: CMFH 
Brain  
o Arrangement of the neurons appears intact with no sings of degeneration or apoptotic 
changes in both the samples 
o Cortex region showed normal neurons with polygonal to round cell bodies containing 
dense cytoplasm. 
 
Lung 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no sings of pulmonary 
edema 
 
Heart 
o No evidence on accumulation of adipose tissue on interstitium 
o No evidence of atherosclerosis and thrombosis 
 
Stomach 
 Gastric glands, gastric glands including secretary sheath appears normal 
 Normal gastric mucosa containing intact gastric gland cells, parietal cells which are 
spherical cell with deeply stained dark nucleus 
Spleen 
 Lymphoid follicles appears normal  
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the samples. 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was normal 
with no significant signs of enlargement 
Liver 
 The walls of the lumen appears normal with no evidence of ischemic changes . 
 No evidence of infiltration 
 Liver parenchyma appears normal with no evidence of necrosis 
Kidney 
 Swollen tubular basement membrane 
 The lining epithelial cells of the renal tubules shown pyknosis of the nuclei 
 
Uterus 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium and blood vessels appears normal 
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Ovary 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and Primordial 
follicles with few mature ovarian follicles with no signs of abnormality.  
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Histopathology of Brain  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Heart  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Lung  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Stomach  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Liver  
Low Power Magnification 10X 
 
High Power Magnification 40X 
 
 
 
OBSERVATION AND RESULT 
 
 Page 128 
 
Histopathology of Kidney  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Spleen  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology of Testes  
Low Power Magnification 10X 
 
High Power Magnification 40X 
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Histopathology Analysis Report 
 
Group ID: C1MMH 
Brain 
 No signs of pyknosis and perineural vacuolization 
 No signs of edema or degeneration were observed. 
 Arrangement of neurons on cerebral cortex appears normal and dense 
 
Heart 
 No evidence on accumulation of adipose tissue on interstitium 
 No evidence of atherosclerosis and thrombosis 
 
Lung 
 Perivascular region appears normal, Alveolar septa and wall appeared widen and normal 
 No signs of lymphocyte cuffing 
Stomach 
 Lumina of blood vessels appears normal. Appearance of glandular lumen was normal 
 Intracytoplasmic zone of mucosa appears normal 
 
Spleen 
 Marginal sinus (MS) of the rat and its sinus lining cells appears normal 
 Erythropoietic cells (EP) are scattered throughout the red pulp of both the samples. No 
abnormalities found in lymph node of both the samples 
 
Liver 
 Liver sinusoid appears widen with occasional bi nucleated hepatocytes 
 Portal vein viewed normal with no evidence of inflammation 
 
Kidney 
 Mild evidence of tubular congestion were observed 
 Swollen tubular basement membrane 
 The lining epithelial cells of the renal tubules shown pyknosis of the nuclei  
 
TESTES 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells and 
spermatogonia were normal 
 No signs of interstitial fibrosis were observed  
 Sperm oriented towards the center of sertoli cells with cluster of tail projected outside was 
observed 
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OBSERVATION AND RESULTS 
Results of the study were observed with respect to the following criteria 
   1. Sex Distribution 
   2. Age Distribution 
   3.Socio-Economical Status 
   4. Occupational Distribution 
   5. Diet 
   6. Thinai 
   7. Paruva kaalam 
   8. Gunam 
   9.Body Constitution 
   10. Naadi 
   11. Distribution of Vali   
   12. Distribution of Azhal 
   13. Distribution of Iyam 
   14. Envagai thervugal 
   15. Neikkuri 
   16. Udhal thaathukkal 
   17. Kanmenthiriyam 
   18. Duration of illness 
   19.  Mode of onset 
   20. Clinical features 
   21. Deformities 
   22. Involvementof Joints 
   23. Results   
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1. SEX  DISTRIBUTION 
 
Sl. No Sex No of Cases Percentage 
1 Male 4           10% 
2 Female 36 90% 
 
 
  
OBSERVATION 
Among 40 patients selected, the disease was found to be in high in females 
(90%) and low in males (10%) 
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2. AGE DISTRIBUTION 
 
Sl. No Age No of Cases Percentage 
1 20-30 years 3 7.5% 
2 31-40 years 12 30% 
3 41-50 years                15 37.5% 
4 51-60 years 10 25% 
 
  
 
Observation: 
7.5 % of patients came under the age group between 20-30 years, 30% of 
patients fell under the age group between 31-40 years, 37.5 % of patients were between 
41-50 years and 40% of patients were between 51-60 years. 
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3. SOCIO ECONOMIC STATUS 
 
Sl. No 
Socio economic 
status 
No of Cases Percentage 
1 Low income 5 12.5% 
2 Moderate income 32 80% 
3 High income 3 7.5% 
 
  
 
Observation:  
In this study the disease were found high in moderate income group and low in 
high income group. 
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4. OCCUPATIONAL DISTRIBUTIONS 
  
Sl. No Nature of Work No. of Cases Percentage 
1 Home Maker 22 55% 
2 Tailor 3 7.5% 
3 Engineer 2 5% 
4 Handloom weavers 1 2.5% 
5 Teacher 2 5% 
6 Coolie 9 22.5% 
7 Lab assistant 1 2.5% 
 
 
 
OBSERVATION: 
Among 40 cases (55%) were home makers, (7.5%) were tailors, (2.5%) were 
handloom workers and lab assistant and (22.5%) of them were coolie 
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5. DIET 
  
Sl. No Dietary Habits No of Cases Percentage 
1 Vegetarian 8 20% 
2 Non Vegetarian 32 80% 
  
 
  
Observation :  
 Among 40 patients, 80% of patients were non vegetarian and 20% of patients 
were vegetarian. 
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6. THINAI 
 
Sl. 
No 
Thinai No. of Cases Percentage 
1 Kurinji (Hill Area) -           - 
2 Mullai (Forest Area) - - 
3 Marutham (Fertile Land) - - 
4 Neithal (Coastal Area) 40 100% 
5 Paalai (Desert Land) - - 
 
  
 
Observation:  
 Among the 40 cases all the cases were from Neithal thinai. 
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7. PARUVA KAALAM 
 
S. S.no Kaalam 
  
No of cases Percentage 
1 Kaarkaalam - - 
       2 Koothirkaalam - - 
      3 Munpanikaalam - - 
      4 Pinpanikaalam 32 80% 
      5 Ilavenilkaalam 8 20% 
      6 Muthuvenilkaalam - - 
 
Observation: 
 Out of 40 cases 80% of the cases were treated in Pinpani kaalam and20% of 
them were treated in Ilavenil kaalam. 
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8. GUNAM 
 
S. S.no Gunam 
 
No of cases Percentage 
1 Sathuvagunam - - 
       2 Rasogunam 40 100% 
      3 Thamogunam - - 
 
 
 
OBSERVATION: 
 In Gunam 100% of cases had Rasogunam. 
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9. YAAKAI ILAKKANAM (BODY CONSTITUTION) 
 
S. S.no Yaakaiilak kanam 
 
No of cases Percentage 
1 Vaathathegi - - 
       2 Pithathegi - - 
      3 Kabathegi - - 
      4 Thonthathegi 40 100% 
 
 
 
Observation 
 Out of 40 cases, all the cases were under Thonthaudal. 
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10. DISTURBANCE OF VAATHAM 
 
S.       S.no Vaatham 
 
No of cases Percentage 
1111    1 Pranan - - 
2 Abanan 2 5% 
3 Uthanan - - 
4 Viyanan 40 100% 
5 Samanan 40 100% 
6 Nagan - - 
7 Koorman - - 
8 Kirugaran 7 17.5% 
9 Devathathan - - 
10 Dhananjeyan - - 
 
 
 
OBERVATION: 
In Vaatham, Viyaanan and Samanan were affected in all 40 cases (100%), 
Abaanan was affected in 5% of cases and kirukaran was affected in 17.5% cases 
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11. DISTURBANCE OFAZHAL: 
 
S.       S.no Pitham 
 
No of cases Percentage 
1111    1 Anarpitham 7 17.5% 
2 Ranjagapitham 40 100% 
3 Sathagapitham 40 100% 
4 Alosagapitham - - 
5 Prasagapitham - - 
 
 
 
OBSERVATION: 
 In Pitham, Anar pitham was affected in (17.5%) of cases, Ranjagapitham was 
affected in (100%) Saathagam was affected in 40 (100%) cases. 
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12. DISTURBANCE OF IYAM 
 
S.       S.no Iyam 
 
No of cases Percentage 
1111    1 Avalambagam - - 
2 Kilethagam - - 
3 Pothagam - - 
4 Tharpagam - - 
5 Santhigam 40 100% 
 
 
 
Observation: 
 In Iyam, santhigam was affected in all cases(100%). 
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13. ENVAGAI THERVUGAL: 
 
Sl. 
No 
EnvagaiThervugal No. of Cases Percentage 
1 Naadi 
 
 
a. Vathapiththam 20 50% 
b. Piththavatham 10 25% 
c. Kabavatham 4 10% 
d. Kabapiththam 6 15% 
2 Sparisam 40 100% 
3 Naa - - 
4 Niram - - 
5 Mozhi - - 
6 Vizhi - - 
7 Malam 2 5% 
8 Moothiram - - 
 
Observation: 
 In Envagaithervugal, Niram and Sparisam were found affected in all the 40 
cases. The Naadinadai seen in Vali Azhal Keel Vaayu patients were Vathapitham 
50%, Pithavatham 25 %,  Kabavatham 10% and Kabapitham15%. 
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14. NEIKKURI 
 
S.       S.no Neikuri 
 
No of cases Percentage 
1111    1 Vaathaneer 
   (Aravenaneendathu) 
8 20% 
2 Pithaneer 
   (Aazhipolparaviyathu) 
- - 
3 Kabaneer 
  (Muthothuninrathu) 
32 80% 
4 Others - - 
 
 
 
Obsevation: 
 Among 40 cases, Vaatha neer was found in 8 cases (20%) and Kaba neer was 
found in 32 cases (80%). 
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15. UDAL THAATHUKKAL 
 
S.       S.no Udalthaathukkal 
 
No of cases Percentage 
1111    1 Saaram 40 100% 
2 Senneer 40 100% 
3 Oon 40 100% 
4 Kozhuppu 20 50% 
5 Enbu 40 100% 
6 Moolai - - 
7 Sukkilam/Suronitham - - 
 
 
 
Observation 
In this study Saaram, Senneer, Oon and Enbu were affected in all 40cases 
(100%). Kozhuppu was affected in 20 cases (50%) 
100% 100% 100%
50%
100%
0% 0%
Udal thathukkal
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 148 
 
16. KANMENTHIRIYAM 
 
S.       S.no Kanmenthiriyam No of cases Percentage 
1111    1 Kai 40 100% 
2 Kaal 40 100% 
3 Vaai - - 
4 Eruvai 2 5% 
5 Karuvai - - 
 
 
 
 
Observation: 
 In Kanmendrium, Kai and Kaal were affected in all 40 cases (100%), Eruvai 
affected in 2 cases (5%). 
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17. DURATION OF ILLNESS 
 
S.       S.no Duration of illness 
 
No of cases Percentage 
1111    1 Upto 6 months 6 15% 
2 6 months – 1 year 13 32.5% 
3 1-2 years 8 20% 
4 2-3 years 8 20% 
5 3-10 years 5 12.5% 
 
 
 
Observation: 
 In this study about 12.5%of cases had 3-10yrs of duration, 20% of cases had 2-
3yrs of duration, 20% of cases had 1-2yrs of duration, 32.5% of cases had 6 months-1yr 
of duration and 15% cases had 6 month of  Duration of illness. 
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18. CLINICAL FEATURES 
S.no Clinical features No of cases Percentage 
1 Pain 40 100% 
2 Swelling 40 100% 
3 Morning stiffness 40 100% 
4 Tenderness 40 100% 
5 Warmth  40 100% 
6 Fever 2 5% 
7 Poly arthralgia 36 90% 
8 Deformity 8 20% 
9 Restricted movement 40 100% 
10 Anorexia 7 17.5% 
 
 
Observation: 
 In this study, all 100% of cases had Pain, Swelling, Early morning Stiffness, 
Warmth, Tenderness and Restricted Movements.  5% of cases had fever, 20% of cases 
had Deformities, 90% of cases had Polyarthralgia symptoms and 17.5% of cases had 
anorexia. 
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19. DEFORMITIES 
 
S.no Deformities No of cases Percentage 
1 Spindle shaped fingers 12 30% 
2 Swan neck deformity 5 12.5% 
3 Z shape deformity - - 
4 Ulnar deviation of hand 18 45% 
5 Hallus vugus 4 10% 
 
 
 
Observation: 
 In this study,30% of cases had Spindle shape deformity,12.5% cases had 
swanneck deformity,45% cases had ulnar deviation and 10% of cases had Hallus valgus 
deformity.  
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20. INVOLVEMENT OF JOINTS 
S.no Name of the joint No of cases Percentage 
1 Cervical vertebra 10 25% 
2 Elbow joint 36 90% 
3 Wrist joint 35 87.5% 
4 Metacarpo phalangeal joint 
(MCP) 
37 92.5% 
5 Ankle joint 36 90% 
6 Proximal interphalangeal joint 
(PIP) 
34 85% 
7 Hip joint 35 87.5% 
8 Lumbosacral joint 15 37.50% 
9 Knee joint 40 100% 
 
 
Observation: 
 In this study, MCP joints was involved in 37 cases (92.5%), Knee joint was 
affected in 100%, Elbow joints were involved in 36 cases (90%) Wrist and hip joints 
was involved in 35 cases (87.5%), Ankle joint was involved in 36 cases (90%), 
Lumbosacral joint was involved in 15 cases (37.5%),PIP were affected in 34(85%) 
casesand Cervical  vertebra wasinvolved in 10 cases (25%). 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
25%
90%
87.50%
92.50% 90% 85% 87.50%
37.50%
100%
INVOLVEMENT OF JOINTS
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 153 
 
21a. PAIN SCORE BEFORE AND AFTER TREATMENT: 
 
S.No OP No NAME 
AGE/ 
SEX 
 PAIN SCORE 
 
RESULTS 
BT AT  
1. 
H42039 MrsKaliselvi 48/F 
8 6 
Moderate 
2. 
H62467 Manjula 38/F 
8 2 
Good 
3. 
I57192 Malliga.C 49/F 
8 6 
Moderate 
4. 
8729 Arunadevi.G 48/F 
9 4 
Moderate 
5. 
D069124 Mumtaj 60/F 
7 2 
Good 
6. 
H7004 V.Amsa 33/F 
8 2 
Good 
7. 
I56347 Balaraman 47/M 
9 5 
Moderate 
8. 
I42435  Mercy Vasantha 60/F 
8 4 
Moderate 
9. 
E04908 Nageahwari 43/F 
9 7 
Mild 
10. 
H94125 V. Shanthi 48/F 
7 3 
Good 
11. 
9471 Ganeshan. R 41/M 
8 2 
Good 
12. 
I85728 Muthulakshmi 35/F 
7 3 
Good 
13. 
H44555 Malarkodi 55/F 
7 4 
Moderate 
14. 
8720 Rani 58/F 
    10 6 
Moderate 
15. 
H57980 S. Malliga 50/F 
9 6 
Moderate 
16. 
I73714 Uma 35/F 
9 4 
Moderate 
17. 
H41678 V.Laxshmi 55/F 
7 3 
Good 
18. 
I73585 Magi 31/F 
8 5 
Moderate 
19. 
8805 Ezhilmathi 37/F 
9 4 
Moderate 
20. 
I72305 Sundararaani 59/F 
7 2 
Good 
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S.No OP No NAME 
AGE/ 
SEX 
 PAIN SCORE 
 
Results 
 
BT AT  
21. 9487 Munusamy.s 46/M 
8 4 
Moderate 
22. I52066 A bhuveneeshwari 37/F 
8 3 
Good 
23. H74965 Sangeetha 52/F 
9 7 
Mild 
24. F44328 Chandra.k 48/F 
7 3 
Good 
25. H17075 Panjavarnam 44/F 
7 2 
Good 
26. I45702 M. Anand 27/M 
8 3 
Good 
27. 8842 Vanitha.m 29/F 
9 6 
Moderate 
28. 9521 C.munusaamy 58/M 
9 8 
Mild 
29. H36596 P.usha 46/F 
8 4 
Moderate 
30. I02495 S.jayanthi 34/F 
8 4 
Moderate 
31. G45724 Papaathi 58/F 
8 3 
Good 
32. I81587 Krithikaa 34/F 
8 3 
Good 
33 I75623 S.selvi 35/F 
7 4 
Moderate 
34. 8864 Kala 29/F 
8 2 
Good 
35. 8868 C.shanthi 45/F 
7 5 
Moderate 
36. 8873 Shagunthala 45/F 
7 1 
Good 
37. G97925 Dhanakodi 59/F 
8 5 
Moderate 
38. 8908 Vasantha 55/F 
8 2 
Good 
39. 8911 Indhra 41/F 
8 4 
Moderate 
40 I68500 R.selvi 37/F 
8 5 
Moderate 
CLINICAL OBSERVATION  AND  RESULT 
 
 Page 155 
 
21b. PAIN SCORE BEFORE AND AFTER TREATMENT 
S.no Pain Scale Before treatment After treatment 
No of cases Percentage No of cases Percentage 
1 Severe pain 28 70% 3 7.5% 
2 Moderate pain 12 30% 20 50% 
3 Mild pain - - 17 42.5% 
4 No pain - - - - 
 
 
Observation: 
 In this study, Before treatment, 28 cases (70%) had severe pain, remaining 12 
cases (30%) had moderate pain. After treatment 3 cases (7.5%) had severe pain, 20 
cases (50%) had Moderate pain and 17 cases (42.5%) had Mild pain. 
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22. GRADING OF MOVEMENTS: 
 
S.No OP No NAME 
AGE/ 
SEX 
GRADING OF 
MOVEMENTS 
BT AT 
1. 
H42039 KALISELVI 48/F 
G3 G2 
2. 
H62467 MANJULA 38/F 
G2 G1 
3. 
I57192 MALLIGA.C 49/F 
G3 G2 
4. 
8729 ARUNADEVI.G 48/F 
G3 G2 
5. 
D069124 MUMTAJ 60/F 
G3 G1 
6. 
H7004 V.AMSA 33/F 
G3 G1 
7. 
I56347 BALARAMAN 47/M 
G3 G2 
8. 
I42435  MERCY VASANTHA 60/F 
G3 G1 
9. 
E04908 NAGEAHWARI 43/F 
G3 G2 
10. 
H94125 V. SHANTHI 48/F 
G2 G1 
11. 
9471 GANESHAN. R 41/M 
G3 G1 
12. 
I85728 MUTHULAKSHMI 35/F 
G2 G1 
13. 
H44555 MALARKODI 55/F 
G3 G1 
14. 
8720 RANI 58/F 
G3 G2 
15. 
H57980 S. MALLIGA 50/F 
G3 G2 
16. 
I73714 UMA 35/F 
G3 G1 
17. 
H41678 V.LAXSHMI 55/F 
G2 G1 
18. 
I73585 MAGI 31/F 
G3 G2 
19. 
8805 EZHILMATHI 37/F 
G3 G1 
20. 
I72305 SUNDARARAANI 59/F 
G3 G1 
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S.No OP No NAME 
AGE/ 
SEX 
GRADING 
BT AT 
21. 9487 MUNUSAMY.S 46/M 
G3 G1 
22. I52066 BHUVENEESHWARI 37/f 
G2 G2 
23. H74965 SANGEETHA 52/F 
G3 G3 
24. F44328 CHANDRA.K 48/F 
G2 G1 
25. H17075 PANJAVARNAM 44/F 
G2 G2 
26. I45702 M. ANAND 27/M 
G3 G1 
27. 8842 VANITHA.M 29/F 
G3 G1 
28. 9521 C.MUNUSAAMY 58/m 
G3 G3 
29. H36596 P.USHA 46/F 
G2 G1 
30. I02495 S.JAYANTHI 34/F 
G2 G1 
31. G45724 PAPAATHI 58/F 
G3 G2 
32. I81587 KRITHIKAA 34/F 
G2 G1 
33 I75623 S.SELVI 35/F 
G2 G1 
34. 8864 KALA 29/F 
G3 G2 
35. 8868 C.SHANTHI 45/F 
G2 G2 
36. 8873 SHAGUNTHALA 45/F 
G3 G1 
37. G97925 DHANAKODI 59/F 
G3 G3 
38. 8908 VASANTHA 55/F 
G3 G1 
39. 8911  INDHRA 41/F 
G3 G2 
40 I68500 R.SELVI 37/F 
G2 G1 
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22a. GRADING OF MOVEMENTS: 
 
Grade 
Before treatment After treatment 
No. of patients Percentage No. of patients Percentage 
 
Grade I 
 
0 
 
0% 
 
23 
 
57.5% 
Grade II  
13 
 
32.5% 
 
14 
 
35% 
Grade III  
27 
 
67.5% 
 
3 
 
7.5% 
Grade IV  
0 
 
0% 
 
0 
 
0% 
 
 
Observation: 
In this study, Before treatment, 13 cases (32.5%) had mild restriction, 27 
(67.5%) had moderate restriction, After treatment 23 (57.5%) cases were fit for all 
activities, 14 (35%) cases hadmoderate restriction. 
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23. Results 
S.no Results No of cases Percentage 
1 Good Improvement 17 42.5% 
2 Moderate Improvement 20 50% 
3 Mild Improvement 3 7.5% 
4 No Improvement - - 
 
 
Observation: 
In this study, 17 cases (42.5%) showed good improvement, 20 cases (50%) 
showed moderate improvement, 3 cases (7.5%) showed mild improvement. 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 Hb(gm/dl) TOTAL 
RBC 
COUNT 
(million/c
u.mm) 
ESR 
(mm/hour) 
TOTAL WBC 
COUNT 
S.N
O 
IP/OP 
NO 
NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT 
1 H42039 KALISELVI 48/F 13.2 13.1 5.0 4.8 20 30 8100 7400 
2 H62467 MANJULA 38/F 11.9 11.3 4.4 4.3 26 24 7,100 7,700 
3 I57192 MALLIGA 49/F 11.8 11.3 4.4 4.6 30 24 6,500 7,000 
4 8729 ARUNADEVI.G 48/F 13.5 11.4 5.3 4.8 24 44 9,300 9,200 
5 D069124 MUMTAJ 60/F 11.8 12.1 4.4 4.4 34 24 6,300 5,800 
6 H7004 V.AMSA 33/F 10.3 11.0 4.5 4.1 20 22 8,600 8,700 
7 I56347 BALARAMAN 47/M 14.9 14.7 5.2 5.1 16 8 7,600 8,000 
8 I42435  MERCY 
VASANTHA 
60/F 13.8 13.1 4.8 4.5 22 10 9200 9,100 
9 E04908 NAGEAHWARI 43/f 12.2 12.3 4.4 4.6 3o 40 7,500 7,900 
10 H94125 V. SHANTHI 48/F 11.4 10.8 4.2 4.0 60 66 8,400 7500 
11 9471 GANESHAN. R 41/M 12.8 12.5 4.5 4.6 34 34 7,700 7,800 
12 I85728 MUTHULAKSHMI 35/F 13.5 13.5 4.4 4.3 30 36 7,900 7,800 
13 H44555 MALARKODI 55/F 12 12.3 4.4 4.1 30 30 6,900 6,100 
14 8720 RANI 58/F 10.3 11.2 4.7 4.5 60 90 6,300 6,400 
15 H57980 S. MALLIGA 50/F 11.8 11 4.4 4.2 12 12 8,600 7,900 
16. I73714 UMA 35/F 12.2 12 4.6 4.8 36 76 6,700 6,700 
17. H41678 V.LAXSHMI 55/F 12.6 12.7 4.9 4.5 50 60 9.500 8,500 
18. I73585 MAGI 31/F 12.8 12.3 4.2 4.5 30 36 8,200 8,400 
19. 8805 EZHILMATHI 37/F 12.0 12.2 4.4 4.8 50 40 7,600 7,000 
20. I72305 SUNDARARAANI 59/F 11 12 4.5 4.5 40 20 4,500 4,600 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 Hb(gm/dl) TOTAL 
RBC 
COUNT 
(million/cu
.mm) 
ESR 
(mm/hou
r) 
TOTAL WBC 
COUNT 
S.N
O 
IP/OP 
NO 
NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT 
21. 9487 MUNUSAMY.S 46/M 12.8 13 4.4 4.6 30 30 8,100 8000 
22. I52066 BHUVENEESHWARI 37/F 9.8 10 4.1 4.4 60 80 9,500 9,000 
23. H74965 SANGEETHA 52/F 12.2 12.0 4.4 4.3 30 40 7,100 8,400 
24. F44328 CHANDRA.K 48/F 12 12.2 4.4 4.2 20 16 7000 6,900 
25. H17075 PANJAVARNAM 44/F 12.8 12.6 4.4 4.3 20 36 6,100 6,800 
26. I45702 M. ANAND 27/M 12.4 12.7 4.5 4.7 20 30 6,400 7,000 
27. 8842 VANITHA.M 29/F 10.4 10.1 4.4 4.2 44 50 8,000 6,200 
28. 9521 C.MUNUSAAMY 58/m 12.2 12.5 4.5 4.6 32 35 6,900 6,700 
29. H36596 P.USHA 46/F 12.7 13.5 4.7 4.9 30 44 7,500 8,800 
30. I02495 S.JAYANTHI 34/F 10 11 4.3 4.2 40 20 4,600 4,500 
31. G45724 PAPAATHI 58/F 12.2 11.6 4.7 4.3 34 24 7,800 6,800 
32. I81587 KRITHIKAA 34/F 12.4 12.5 4.4 4.5 60 30 6,800 6,900 
33 I75623 S.SELVI 35/F 10.4 10,7 4,5 4.5 20 30 6000 6500 
34. 8864 KALA 29/F 10.6 10.6 4.6 4.5 34 38 6,400 6500 
35. 8868 C.SHANTHI 45/F 11 11.6 4.2 4.4 16 8 6,400 6,200 
36. 8873 SHAGUNTHALA 45/F 10.9 11.9 4.2 4.4 24 30 9,000 8,700 
37. G97925 DHANAKODI 59/F 11.1 11.2 4.4 4.3 20 20 5,600 5,700 
38. 8908 VASANTHA 55/F 12.5 12.5 4.4 4.5 30 28 6,900 6,900 
39. 8911  INDHRA 41/F 12.5 12 4.4 4.5 10 8 9,400 9,100 
40 I68500 R.SELVI 37/F 10 12 4.6 4.5 10 20 6,600 6,700 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 BLOOD 
GLUCOSE
(F) 
BLOOD 
GLUCOS
E(PP) 
UREA CREATI
NINE 
TOTAL 
CHOLES
TROL 
S.N
O 
IP/OP 
NO 
NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT BT AT 
1 H42039 MRS KALISELVI 48/f 104 102 124 122 14 14 0.7 0.8 180 192 
2 H62467 MANJULA 38/F 97 97 145 109 14 24 0.6 0.8 137 145 
3 I57192 MALLIGA 49/F 101 108 110 129 19 21 0.7 0.9 145 149 
4 8729 ARUNADEVI.G 48/F 110 108 136 128 26 29 1.1 1.1 167 158 
5 D069124 MUMTAJ 60/F 103 113 123 121 18 16 0.8 0.9 148 126 
6 H7004 V.AMSA 33/F 110 108 120 128 17 12 1 0.9 195 168 
7 I56347 BALARAMAN 47/M 92 84 79 91 19 21 1 1.1 185 178 
8 I42435  MERCY 
VASANTHA 
60/F 111 112 127 149 16 20 0.8 0.9 214 199 
9 E04908 NAGEAHWARI 43/f 124 112 146 140 12 15 0.8 1 154 149 
10 H94125 V. SHANTHI 48/F 101 92.8 151 120 30.
5 
25.
4 
0.9 0.9 172 133 
11 9471 GANESHAN. R 41/M 102 100 102 97 15 16 1.1 0.9 124 131 
12 I85728 MUTHULAKSH
MI 
35/F 102 109 128 132 23 27 1 1.1 145 143 
13 H44555 MALARKODI 55/F 64 78 81 90 15 17 0.8 0.9 138 140 
14 8720 RANI 58/F 82 89 102 110 23 32 1 0.9 143 153 
15 H57980 S. MALLIGA 50/F 98 101 110 127 27 23 1 0.9 154 147 
16. I73714 UMA 35/F 97 101 140 128 13 12 0.6 0.9 128 129 
17. H41678  V.LAXSHMI 55/F 98 90 128 127 17 18 0.9 1 216 210 
18. I73585 MAGI 31/F 89 83 98 121 10 11 0.7 0.8 144 125 
19. 8805 EZHILMATHI 37/F 99 101 110 121 21 25 0.9 0.9 174 162 
20. I72305 SUNDARA 
RAANI 
59/F 101 118 129 132 27 29 0.9 1 145 154 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 BLOOD 
GLUCOS
E(F) 
BLOOD 
GLUCOS
E(PP) 
UREA CREATI
NINE 
TOTAL 
CHOLES
TROL 
S.N
O 
IP/OP 
NO 
 NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT BT AT 
21 9487 MUNUSAMY.S 46/M 109 110 121 134 12 14 1.2 1 143 154 
22 I52066 BHUVENEESH 
WARI 
37/F 89 85 108 110 26 24 0.9 0.9 159 160 
23 H74965 SANGEETHA 52/F 115 103 140 107 21 17 0.9 0.9 179 149 
24 F44328 CHANDRA.K 48/F 88 80 101 110 15 15 0.7 0.8 194 218 
25 H17075 PANJAVARNAM 44/F 99 89 101 97 15 16 0.9 0.7 125 126 
26 I45702 M. ANAND 27/M 102 105 103 110 21 19 1.1 0.9 146 140 
27 8842 VANITHA.M 29/F 88 80 101 110 12 19 0.8 0.7 116 139 
28 9521 C.MUNUSAAMY 58/m 84 88 83 98 21 19 1.1 0.9 146 140 
29 H36596 P.USHA 46/F 109 101 123 114 15 15 0.7 0.8 194 218 
30 I02495 S.JAYANTHI 34/F 96 110 111 123 13 15 0.7 0.7 120 126 
31 G45724 PAPAATHI 58/F 98 85 121 128 17 10 0.5 0.6 145 167 
32 I81587 KRITHIKAA 34/F 84 88 83 98 19 16 0.9 0.8 124 120 
33 I75623 S.SELVI 35/F 89 98 102 110 20 19 0.8 0.8 145 143 
34 8864 KALA 29/F 100 90 110 100 13 13 0.7 0.8 138 140 
35 8868 C.SHANTHI 45/F 98 95 110 110 15 14 0.5 0.5 158 143 
36 8873 SHAGUNTHALA 45/F 83 90 100 120 12 13 0.8 0.7 160 154 
37 G97925 DHANAKODI 59/F 98 85 121 128 12 10 0.9 0.9 145 157 
38 8908 VASANTHA 55/F 103 98 130 105 24 22 1.0 0.9 189 173 
39 8911  INDHRA 41/F 100 95 120 112 18 16 0.7 0.7 167 159 
40 I68500 R.SELVI 37/F 88 90 91 95 9 11 0.8 0.9 140 127 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 TOTAL 
BILIRUBIN 
CALCIU
M 
PHOSPHO
RUS 
URIC 
ACID 
S.N
O 
IP/OP 
NO 
 NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT 
1 H42039 MRS KALISELVI 48/f 0.6 0.5 9.3 9.7 3.7 3.3 3.0 3.2 
2 H62467 MANJULA 38/F 0.3 0.3 7.9 8.5 3.6 3.2 2.3 3.4 
3 I57192 MALLIGA 49/F 0.8 0.7 8.9 9.2 3.9 4.1 4.5 4.3 
4 8729 ARUNADEVI.G 48/F 0.5 0.4 7.7 8.6 4.1 4.2 5.0 4.2 
5 D069124 MUMTAJ 60/F 0.4 0.4 4.2 9.2 5.2 3.3 3.5 3.7 
6 H7004 V.AMSA 33/F 0.3 0.5 8.1 8 5.8 5.4 3.2 4 
7 I56347 BALARAMAN 47/M 0.7 0.6 9.2 7.9 4 3.2 7.2 8.1 
8 I42435  MERCY 
VASANTHA 
60/F 0.4 0.4 8.4 8.1 3.6 3.6 4.7 5.2 
9 E04908 NAGEAHWARI 43/f 1 0.9 8.5 8 3.3 3 4.3 4 
10 H94125 V. SHANTHI 48/F 0.39 0.47 9.2 7.9 3.63 3.51 5.1 4.2 
11 9471 GANESHAN. R 41/M 0.5 0.5 10.2 9.9 3.3 3.3 5.7 5.6 
12 I85728 MUTHULAKSHMI 35/F 0.5 0.4 10.1 9 3.8 3.6 3 3.2S 
13 H44555 MALARKODI 55/F 0.2 0.4 7.8 8.3 5.1 4.9 2.2 3 
14 8720 RANI 58/F 0.6 0.7 8.2 8.5 4.7 4.5 3.1 3.1 
15 H57980 S. MALLIGA 50/F 0.8 0.8 9.1 9.2 4.1 4.3 5.1 4.5 
16 I73714 UMA 35/F 0.4 0.5 7.8 8 2.8 3 4.1 4.5 
17 H41678  V.LAXSHMI 55/F 0.3 0.4 8.6 8.3 3.4 4 5.2 5.2 
18 I73585 MAGI 31/F 0.7 0.7 8.2 9.2 2.7 3.8 4.4 4.2 
19 8805 EZHILMATHI 37/F 0.2 0.4 8.4 8 3.4 3.2 2.6 3 
20 I72305 SUNDARARAANI 59/F 0.9 0.7 7.2 7.7 3.9 4.5 4.9 4.5 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 TOTAL 
BILIRUBI
N 
CALCIU
M 
PHOSPH
ORUS 
URIC ACID 
S.N
O 
IP/OP 
NO 
NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT 
21 9487 MUNUSAMY.S 46/M O.9 O.7 9.8 9.9 4.9 4.9 6.1 5.5 
22 I52066 BHUVENEESH 
WARI 
37/F 0.5 0.4 8.4 8.3 4.3 3.9 6.8 5.9 
23 H74965 SANGEETHA 52/F 0.3 0.3 9.3 8.9 4 4 3.7 4.3 
24 F44328 CHANDRA.K 48/F 0.6 0.4 7.8 8.5 3.9 41 4.5 4.5 
25 H17075 PANJAVARNAM 44/F 0.4 0.6 9 8.7 3.1 3.9 3.7 8.9 
26 I45702 M. ANAND 27/M 0.4 0.5 8.1 8 3.3 3.5 6.5 6.3 
27 8842 VANITHA.M 29/F 0.3 0.3 8 9 3.7 3.9 4.9 4.6 
28 9521 C.MUNUSAAMY 58/m 0.8 0.8 7.1 7.5 3.9 4.2 5.1 5.1 
29 H36596 P.USHA 46/F 0.3 0.3 8 8.7 3 3.7 4.7 4.9 
30 I02495 S.JAYANTHI 34/F 0.2 0.2 8.2 8 3.3 3 5.1 5.3 
31 G45724 PAPAATHI 58/F 0.8 0.7 7.0 7.2 4.2 4.2 4.3 4.3 
32 I81587 KRITHIKAA 34/F 0.4 0.7 8.4 7.9 2.7 3 3.6 4 
33 I75623 S.SELVI 35/F 0.8 0.7 7.3 7.5 3.5 3.5 4.1 4.5 
34 8864 KALA 29/F 0.5 O.6 7.9 7.9 3.8 3.7 4.5 4.1 
35 8868 C.SHANTHI 45/F 0.9 0.7 8.5 8.7 4.1 42 3.5 3.5 
36 8873 SHAGUNTHALA 45/F 1.0 0.9 7.3 7.6 3.9 3.9 4.5 4.3 
37 G97925 DHANAKODI 59/F 0.6 0.6 8.5 8.6 3.5 3.3 4 4.5 
38 8908 VASANTHA 55/F 0.8 0.6 7.3 7.5 3.9 4.2 5.5 5.4 
39 8911  INDHRA 41/F 0.4 0.4 8.1 8.5 4.6 4.5 5.1 4.8 
40 I68500 R.SELVI 37/F 0.4 0.5 8.3 8.4 5 5.3 3 3.3 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 SGOT SGPT ALKALINE 
PHOSPHAT
ASE 
S.NO IP/OP 
NO 
 NAME AGE/ 
SEX 
BT AT BT AT BT AT 
1 H42039 MRS KALISELVI 48/f 21 24 22 28 101 111 
2 H62467 MANJULA 38/F 14 14 11 11 72 76 
3 I57192 MALLIGA 49/F 12 15 13 13 90 95 
4 8729 ARUNADEVI.G 48/F 20 20 18 17 115 118 
5 D069124 MUMTAJ 60/F 28 28 23 21 78 72 
6 H7004 V.AMSA 33/F 14 13 16 18 75 87 
7 I56347 BALARAMAN 47/M 12 14 15 19 100 109 
8 I42435  MERCY VASANTHA 60/F 64 14 11 18 79 77 
9 E04908 NAGEAHWARI 43/f 15 14 17 19 63 72 
10 H94125 V. SHANTHI 48/F 8.1 10.
2 
10.1 6.2 77 69 
11 9471 GANESHAN. R 41/M 13 15 8 8 85 89 
12 I85728 MUTHULAKSHMI 35/F 24 24 27 30 60 76 
13 H44555 MALARKODI 55/F 9 11 11 13 97 98 
14 8720 RANI 58/F 10 12 15 14 85 81 
15 H57980 S. MALLIGA 50/F 25 21 19 17 95 99 
16. I73714 UMA 35/F 13 14 11 12 92 87 
17. H41678  V.LAXSHMI 55/F 17 18 13 18 93 98 
18. I73585 MAGI 31/F 18 17 20 16 67 62 
19. 8805 EZHILMATHI 37/F 13 16 26 24 91 90 
20. I72305  SUNDARARAANI 59/F 15 14 13 15 87 90 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 SGOT SGPT ALKALINE 
PHOSPHATAS
E 
S.N
O 
IP/OP 
NO 
 NAME AGE/ 
SEX 
BT AT BT AT BT AT 
21 9487 MUNUSAMY.S 46/M 29 25 25 21 115 112 
22 I52066 Mrs.A 
BHUVENEESHWARI 
37/F 15 12 12 14 108 110 
23 H74965 SANGEETHA 52/F 10 13 11 6 109 113 
24 F44328 CHANDRA.K 48/F 15 14 13 13 85 85 
25 H17075 PANJAVARNAM 44/F 32 18 42 23 90 70 
26 I45702 M. ANAND 27/M 10 15 17 19 49 57 
27 8842 VANITHA.M 29/F 17 26 14 18 82 69 
28 9521 C.MUNUSAAMY 58/M 12 11 13 14 76 72 
29 H36596 P.USHA 46/F 12 16 18 11 119 120 
30 I02495 S.JAYANTHI 34/F 22 23 21 20 55 60 
31 G45724 PAPAATHI 58/F 18 16 15 13 85 82 
32 I81587 KRITHIKAA 34/F 14 18 15 13 57 47 
33 I75623 S.SELVI 35/F 11 12 14 13 87 90 
34 8864 KALA 29/F 27 24 22 22 115 110 
35 8868 C.SHANTHI 45/F 18 18 16 14 83 80 
36 8873 SHAGUNTHALA 45/F 6 7 11 10 63 63 
37 G97925 DHANAKODI 59/F 25 26 7 8 101 99 
38 8908 VASANTHA 55/F 9 10 11 12 65 64 
39 8911  INDHRA 41/F 21 20 18 17 89 87 
40 I68500 R.SELVI 37/F 18 15 13 17 54 60 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 
 
URINE 
SUGUR(R) 
URINE 
SUGUR(PP) 
ALBUMIN DEPOSITS 
Epithelia
l cells 
Pus cells 
S.N
O 
IP/OP 
NO 
 NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT BT AT 
1 H42039 Kaliselvi 48/f NIL NIL NIL NIL NIL NIL 1-2 1-3 1-2 1-3 
2 H62467 Manjula 38/F NIL NIL NIL NIL NIL NIL 1-4 1-2 1-2 1-2 
3 I57192 Malliga 49/F NIL NIL NIL NIL NIL NIL 2-5 1-2 3-4 1-3 
4 8729 Arunadevi.G 48/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-3 1-3 
5 D069124 Mumtaj 60/F NIL NIL NIL NIL NIL NIL 1-5 1-3 2-1 1-2 
6 H7004 V.Amsa 33/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
7 I56347 Balaraman 47/M NIL NIL NIL NIL NIL NIL 2-6 2-5 1-3 1-3 
8 I42435  Mercy 
Vasantha 
60/F NIL NIL NIL NIL NIL NIL 2-4 1-3 2-3 1-2 
9 E04908 Nageahwari 43/f NIL NIL NIL NIL NIL NIL 1-2 1-3 1-2 1-2 
10 H94125 V. Shanthi 48/F NIL NIL NIL NIL NIL NIL 1-5 1-3 1-2 1-2 
11 9471 Ganeshan. R 41/M NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
12 I85728 Muthulakshmi 35/F NIL NIL NIL NIL NIL NIL 2-6 2-4 1-2 1-3 
13 H44555 Malarkodi 55/F NIL NIL NIL NIL NIL NIL 2-4 2-3 1-2 1-2 
14 8720 Rani 58/F NIL NIL NIL NIL NIL NIL 2-7 2-3 2-3 2-3 
15 H57980 S. Malliga 50/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
16 I73714 Uma 35/F NIL NIL NIL NIL NIL NIL 1-2 1-2 2-3 1-2 
17 H41678 V.Laxshmi 55/F NIL NIL NIL NIL NIL NIL 2-4 2-4 2-3 2-3 
18 I73585 Magi 31/F NIL NIL NIL NIL NIL NIL 1-2 1-2 2-3 2-3 
19 8805 Ezhilmathi 37/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
20 I72305 Sundararaani 59/F NIL NIL NIL NIL NIL NIL 2-6 2-4 1-3 1-2 
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LABORATORY INVESTIGATION OP AND IP- BEFORE AND AFTER 
TREATMENT 
 
 URINE 
SUGUR(R) 
URINE 
SUGUR(PP) 
ALBUMIN DEPOSITS 
Epithelia
l cells 
Pus cells 
S.N
O 
IP/OP 
NO 
NAME AGE/ 
SEX 
BT AT BT AT BT AT BT AT BT AT 
21 9487 Munusamy.S 46/M NIL NIL NIL NIL NIL NIL 1-3 1-3 1-2 1-2 
22 I52066 Bhuveneeshw
ari 
37/F NIL NIL NIL NIL NIL NIL 1-3 1-3 1-3 1-3 
23 H74965 Sangeetha 52/F NIL NIL NIL NIL NIL NIL 1-3 1-3 1-2 1-2 
24 F44328 Chandra.K 48/F NIL NIL NIL NIL NIL NIL 2-3 1-3 1-2 1-2 
25 H17075 Panjavarnam 44/F NIL NIL NIL NIL NIL NIL 1-3 1-3 1-3 1-3 
26 I45702 M. Anand 27/M NIL NIL NIL NIL NIL NIL 2-4 2-4 1-3 1-2 
27 8842 Vanitha.M 29/F NIL NIL NIL NIL NIL NIL 1-3 1-4 1-2 1-3 
28 9521 C.Munusaamy 58/M NIL NIL NIL NIL NIL NIL 1-3 1-3 1-2 1-2 
29 H36596 P.Usha 46/F NIL NIL NIL NIL NIL NIL 1-3 1-3 2-3 2-3 
30 I02495 S.Jayanthi 34/F NIL NIL NIL NIL NIL NIL 2-4 2-4 1-3 1-3 
31 G45724 Papaathi 58/F NIL NIL NIL NIL NIL NIL 2-4 2-4 1-3 1-2 
32 I81587 Krithikaa 34/F NIL NIL NIL NIL NIL NIL 2-3 1-2 2-3 1-2 
33 I75623 S.Selvi 35/F NIL NIL NIL NIL NIL NIL 4-6 4-6 2-3 2-3 
34 8864 Kala 29/F NIL NIL NIL NIL NIL NIL 1-3 1-3 1-2 1-2 
35 8868 C.Shanthi 45/F NIL NIL NIL NIL NIL NIL 1-3 1-3 2-3 2-3 
36 8873 Shagunthala 45/F NIL NIL NIL NIL NIL NIL 3-5 1-2 1-3 1-3 
37 G97925 Dhanakodi 59/F NIL NIL NIL NIL NIL NIL 1-3 1-4 2-3 2-3 
38 8908 Vasantha 55/F NIL NIL NIL NIL NIL NIL 2-3 2-3 1-2 1-2 
39 8911 Indhra 41/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-2 1-2 
40 I68500 R.Selvi 37/F NIL NIL NIL NIL NIL NIL 1-2 1-2 1-3 1-3 
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S.NO IP/OP 
NO 
NAME AGE/ 
SEX 
ASO CRP RA FACTOR 
BT AT BT AT BT AT 
      
1 H42039 Kaliselvi 48/f - - + + + + 
2 H62467 Manjula 38/F - - + + + + 
3 I57192 Malliga 49/F - - + + + + 
4 8729 Arunadevi.G 48/F - - + + + + 
5 D069124 Mumtaj 60/F -- -- + + + + 
6 H7004 V.Amsa 33/F - - + + + + 
7 I56347 Balaraman 47/M - - + + + + 
8 I42435 Mercy Vasantha 60/F - - + + + + 
9 E04908 Nageahwari 43/f + + + + + + 
10 H94125 V. Shanthi 48/F - - + + + + 
11 9471 Ganeshan. R 41/M - - + + + + 
12 I85728 Muthulakshmi 35/F - - + + + + 
13 H44555 Malarkodi 55/F - - + + + + 
14 8720 Rani 58/F - - + + + + 
15 H57980 S. Malliga 50/F + + + + + + 
16 I73714 Uma 35/F - - + + + + 
17 H41678 V.Laxshmi 55/F - - + + + + 
18 I73585 Magi 31/F - - + + + + 
19 8805 Ezhilmathi 37/F + + + + + + 
20 I72305 Sundararaani 59/F - - + + + + 
  
LABORATORY INVESTIGATION 
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21 9487 Munusamy.S 46/M - - + + + + 
22 I52066 Bhuveneeshwari 37/F - - + + + + 
23 H74965 Sangeetha 52/F - - + + + + 
24 F44328 Chandra.K 48/F + + + + + + 
25 H17075 Panjavarnam 44/F - - + + + + 
26 I45702 M. Anand 27/M - - + + + + 
27 8842 Vanitha.M 29/F - - + + + + 
28 9521 C.Munusaamy 58/M - - + + + + 
29 H36596 P.Usha 46/F - - + + + + 
30 I02495 S.Jayanthi 34/F - - + + + + 
31 G45724 Papaathi 58/F - - + + + + 
32 I81587 Krithikaa 34/F - - + + + + 
33 I75623 S.Selvi 35/F - - + + + + 
34 8864 Kala 29/F + + + + + + 
35 8868 C.Shanthi 45/F - - + + + + 
36 8873 Shagunthala 45/F - - + + + + 
37 G97925 Dhanakodi 59/F - - + + + + 
38 8908 Vasantha 55/F - - + + + + 
39 8911 Indhra 41/F - - + + + + 
40 I68500 R.Selvi 37/F - - + + + + 
 
STATICAL ANALYSIS 
 
 Page 172 
 
STATISTICAL ANALYSIS 
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to perform 
statistical analysis. Basic descriptive statistics include frequency distributions and 
cross-tabulations were performed. The quantity variables were expressed as Mean ± 
Standard Deviation and qualitative data as percentage. A probability value of <0.05 
was considered to indicate as statistical significance. Paired ‘t’ test was performed for 
determining the significance between before and after treatment.  
 
Paired Sample Statistics (pain scale) Score before Treatment and After 
Treatment) 
 
Variable Obs Mean±SD t Value p Value 
Before treatment 40 8±0.7845 
T=19.133 P<0.0001 
After treatment 40    3.95±1.663 
 
The mean± standard deviation of pain scale score at before and after treatment 
were 8±0.7845and3.95±1.663 respectively which is statistically significant (t=19.133, 
p<0.0001).  
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DISCUSSION 
The Aim of the study is to Evaluate the Therapeutic efficacy of the drug 
“Vaatha Chooranam” in reducing the pain and restricted movement in treating Vali 
Azhal Keel Vaayu. The clinical features of Vali Azhal Keel Vaayu in siddha literature 
can be correlated to Rheumatoid Arthritis in modern science. Rheumatiod Arthritis is 
a chronic inflammatory destructive and deforming polyarthritis Associated with 
symmetrically involved joints. 
Vali Azhal Keel Vaayu is a vaatha disease which causes derangements of 
Vaathakutram which causes increasing pitham and kabam kutram. 
Vaathathathu is responsible for the functioning of udal Thathukal uniformly 
derangement of Vaatha kutram leads to  pricking pain over the body, body ache and 
increase in Pitha kutram causes swelling and increased body temperature, finally 
Kaba kutram accompanies causing stiffness, restricted of movements. 
As Vali Azhal Keel Vaayu is a Auto immune disease  drugs which possess the 
property of Anti-vaatha, Anti-inflammatory, Analgesic, Anti-oxidant property as 
mentioned in siddha literature were selected and the trail drug were prepared by the 
Author in the Gunapadam practical laboratory of  National Institute of Siddha, after 
getting proper authentication of raw drugs from the Medicinal botany department at 
NIS, Chennai 47, under the supervision of the members of the teaching faculty and 
guided by the Head of the Department of Sirappu Maruthuvam of the National 
Institute of Siddha, Chennai - 47. The trial drug was prepared by the standard 
operating procedure as mentioned in the protocol. 
The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
 The Preclinical toxicity studies (Acute toxicity) for the above said trial drug 
was conducted at National Institute of Siddha, after getting the proper acceptance and 
permission from the Institutional Animal Ethical Committee (IAEC). The trial drug 
was proved to be safe for human beings from the observations made from the study. 
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The Biochemical qualitative and quantitative analysis were done at the 
biochemistry lab of NIS and IIT Chennai respectively. It revealed the presence of 
effective minerals and the existence of the drug molecules at micro level. 
              The clinical study was conducted with a well-defined protocol and a proper 
proforma after the approval of the Institutional Ethical Committee. After screening 
patients reporting at the OPD of department of Sirappu Maruthuvam, 40 cases were 
selected for induction to the trial. Before enrolment into the trial the informed consent 
was obtained from the patients. 
 40 patients of both genders were recruited for this study. Among the 40 
patients 28 were OPD patients and the remaining 12 were IPD patients. For In-
Patients, who were not in a situation to stay in the hospital for a long time, were 
advised to attend the Out-Patient Department of Sirappu Maruthuvam for further 
follow- up.  
            The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms. Before treatment the patients were advised to take 
Meganathakulikai– 2 od with hot water in early morning for purgation. On that day 
patient was advised to take rest without internal medicine. 
The patients were treated with trial drugs Vaatha Chooranam twice a day with 
honey and Vaatha Mega Narayana Ennai(external) for 48 days . Patients were 
instructed to take the medicines regularly, advised to follow pathiyam (avoid 
tamarind, tubers, etc.) and advised to avoid cold exposure .Out-Patients were asked to 
visit the hospital once in 7 days. For Out-Patients the drugs were given for 48 days 
and the clinical assessment was done on 0
th
 day, 8
th
 day, 15
th
 day, 22
th
 day , 29
th
 day, 
36
th
 day, 43
th
 day and 49
th
 day.  
  After the treatment, the patients were advised to visit the Out-Patient ward of 
Department of Sirappu Maruthuvam for next 2 months for follow-up. 
 From this study, Among the 40 cases, the Gender of the disease was found to 
be higher in females (90%) and lower in males (10%). 
    In Age group, 7.5% of the affected patients came under the age group 
between 20-30 years. 30 % of the patients fall under the age group between 31-40 
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years, 37.5 % of them were between 41-50 years and 25 % of them were between 51-
60 years. 
    In my study while seeing socio-economic status  of the patients the disease 
was found to be in 80% of Middle income group .7.5 % of casesin high income group  
and 12.5%. cases in the low income group. 
In Occupational  distribution,Among 40 cases 55% were homemakers, 7.5. % 
were tailors, 2.5% were handloom workers and lab assistant and 22.5% of them were 
coolie 
In diet Non vegetarian 80% were very higher than the vegetarian 20%. 
In Thinai all the 100% of cases were from Neithal thinai which mention that 
vaatha disease are common in Neithal thinai 
 In ParuvaKaalam (Season)Out of 40 cases 80% of cases were taken in 
Pinpani kaalam and 20% of cases were taken in Ilavenil kaalam. 
In Gunam all the cases had Rasogunam,. 
 In Body constitution all 100% of cases,  were under Thonthathegi. 
In vaatham,Viyaanan and Samanan was affected in all cases 100%, Abanan 
affected in  5% and Kirkaran was affected in 17.5% 
  In Azhal, Ranjagampitam, Saathagapitham was affected in all  cases 100% and 
Anarpitham was affected in 17.5%. 
In Iyam, Santhigam was affected in all the cases 100%. 
In Envagai Thervu, Vathapithanaadi was found in 50% of cases, 
Pithavathanaadi was found in 25%, kabapithamnaadi was found in 15% of cases and 
kaba vaatham in 10%. Sparisam was affected in all cases 100% and Malam was 
affected (constipation) in 5% of patients.   
In Neikkuri Vathaneer was found in 20% of cases, Kabaneer was  found in 
80% of cases. 
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In Udalthaathukkal Saram, Seneer, Oon, and Enbu were affected in 100% of 
cases and  kozhuppu was affected in 50%of cases. 
           In Kanmendrium Kai and Kaal were affected in 100% of cases, and karuvaai 
affected in 5% of cases 
In Duration of illness, about 12.5% cases had 3-10 yrs of duration, 20% cases 
had  2-3 yrs of duration, 20% cases had 1-2 yrs of duration,  32.5% cases had  6 mon 
– 1yr of duration and  15% cases had 6 months of duration. 
According to the clinical featuresall 100% of cases had pain, swelling, early 
morning stiffness, warmth, tenderness, and restricted movements. 5% cases had fever,  
cases , 20% cases had deformities, 90% cases had polyarthralgia and 17.5% cases had 
anorexia symptoms 
Among the Deformities, 30% of cases had spindle shaped deformity, 10% of 
cases had hallus valgus derormity, 45% of cases had ulnar deviation and  12.5% of 
cases had swan neck  deformity. 
 In Joint involvement,wrist was affected in 87.5%, MCP joints were involved 
in 92.5% cases, Knee joint 100%, PIP joints were  in 85% , Ankle joint was involved 
in 90% cases,  Elbow joint was involved in 90% cases , Lumbosacral joint was  
involved in 15% cases,  Cervical vertebrae were involved in 25% cases, and  Hip joint 
was involved in 35% cases. 
In this study, Before treatment, 70% of cases had severe pain remaining  cases 
30% had moderate pain. After treatment 7.5% had severe pain, 50% had Moderate 
pain and 42.5% had Mild pain. 
In this study, Before treatment, 32.5% of cases had mild restriction, 67.5% had 
moderate restriction, After treatment 57.5% cases were fit for all activities, 35% 
ofcases had moderate restriction. 
Overall Results are 25% cases showed Good improvement50% cases showed  
Moderate  improvement, 17.5%  cases showed  Mild  improvement. 
Laboratory investigation of blood and urine were done for all 40 cases. There 
were no significant changes in blood and urine parameters before and after treatment. 
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The pain assessment was done in all the 40 patients participated in the trial 
The mean pain score before treatment is 8 after treatment it is reduced to 3.95.  
The acute toxicity study was conducted for the trial drug Vali Azhal Keel 
Vaayu in National Institute of Siddha and it showed no abnormal results. Hence the 
safety of the trial drug was also proved. 
 
 
  
 
. 
 
SUMMARY 
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SUMMARY 
 
 The disease Vali Azhal Keel Vaayu was taken for the clinical study with 
Vaatha Chooranam as internal medicine and Vaatha Mega Narayana Ennai as 
external application. For the clinical study, 40 cases were selected based on the 
approved protocol. 
 This study has been approved by IEC of NIS [Date of IEC Approval & its 
number: NIS/IEC/9-2014-15/12-26.08.2015]. Animal studies were carried out after 
obtaining approval from the Institutional Animal Ethical Committee (IAEC) and the 
trial was registered in Clinical Trial Registry of India (CTRI/2017/05/008594.) 
Hence the study is safely executed on patients and there was no adverse drug 
reactions noted during the study period. 
 The toxicological evaluations were conducted as per WHO guidelines for 
safety evaluation of Vaatha Chooranam. In short term and long term toxicity study, 
no signs of  toxicity and mortality were observed through out the study. 
In organs of Control group, no abnormality was detected. The normal 
histological structure present in test group of animals.     
 40 cases, were treated with trial medicine in OPD, IPD of Department of 
Sirappu Maruthuvam, Ayothidoss Pandithar Hospital of National Institute of Siddha, 
Chennai-47. The detailed study on Vaatha Chooranam with reference to its 
aetiology, pathogenesis, investigations, clinical features, diagnosis and treatment 
with trial drugs were done.  
 The patients were diagnosed and included on the basis of  EULAR 
(European league Against Rheumatism scale) and the results were observed by Pain 
scale and restricted movements scale before and after treatment. Among the 40 cases 
treated, 42.5%% cases shows Good improvement, and 50% shows Moderate 
improvement 7.5% shown Mild improvement. 
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CONCLUSION 
 
This study proved that the formulation given good results in many patients 
through clinical trials and it may be better solution for reducing the pain, swelling and 
restricted movements. This brought confident in rheumatoid patients which increases 
the quality of life. 
No adverse effects were noted during the course of treatment. Short term and 
long term study of the trial drug is safe, it does not produce any toxic effects in rats. 
This shows that the trial drug Vaatha Chooranam (Internal) and Vaatha Mega 
Narayana Ennai (External) both is safest drug for human beings.   
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NATIONAL INSTITUTE OF SIDDHA  AYOTHIDOSS PANDITHAR 
HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VAATHA 
CHOORANAM” (INTERNAL) AND “VAATHA MEGA NARAYANA ENNAI” (EXTERNAL) IN 
THE TREATMENT OF “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS) 
Principal Investigator: Dr.T.R.Nishitha 
FORM I- SCREENING & SELECTION PROFOMA 
1. SERIAL NO:      2.OP/IPNO:                             
3. NAME:       4.AGE/GENDER:   
5.OCCUPATION:            6. INCOME: 
7. ADDRESS AND CONTACT NO:  
INCLUSION CRITERIA: 
 Age: 20- 60 years        YES/NO. 
 Sex: Both male and female       M/F 
 Any of the following three symptoms     
Pain and swelling in three or more joint     YES/NO 
Morning Stiffness        YES/NO 
Rheumatoid factor positive       YES/NO 
Deformities like Swan neck and Butttonhole deformity   YES/NO 
Rheumatoid nodules        YES/NO 
 Symmetrical joints involvement      YES/NO                                              
 patient willing to undergo laboratory Investigation    YES/NO 
 Patient willing to sign the informed consent.      YES/NO 
 
EXCLUSION CRITERIA: 
 Pregnancy and lactation        YES/NO  
 Tubercular arthritis       YES/NO 
 Gouty arthritis        YES/NO 
 Diabetic Mellitus        YES/NO 
  Malignant Hypertension       YES/NO 
 Any other systemic illness      YES/NO 
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ADMITTED TO TRAIL      YES   NO 
 
 
          
IF YES                              OPD              IPD 
      
 
 
Date:  
        
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:     Signature of the HOD                                            
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, 
CHENNAI  –  600 047. 
                            DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VAATHA 
CHOORANAM”(INTERNAL) AND“VAATHA MEGA NARAYANA ENNAI”(EXTERNAL) IN 
THE TREATMENT OF“VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS) 
Principal Investigator: Dr.T.R.Nishitha 
FORM II- – HISTORY TAKING PROFORMA 
 
1. SI NO : --------    2 OP \IP NO : --------  
3. NAME: --------    3. AGE /SEX : ------- 
4. OCCUPATION :---------      5. MARITAL STATUS: Married/unmarried  
COMPLAINS AND DURATION 
 
PERSONAL HISTORY: 
PERSONAL HABITS YES NO 
IF YES SPECIFY 
DURATION 
AMOUNT/Quantity 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction     
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 
 
FAMILY HISTORY: 
 Whether this problem runs in family?         1. Yes                               2.No         
If yes, mention the relationship of affected person(s) 
1._________________                                                           2._________________ 
DIETARY HABIT:     
                    1.Vegetarian                                              2.Non-vegetarian 
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MENSTRUAL AND OBSTETRIC HISTORY: 
 
 
 
Date:  
         
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG “VAATHA CHOORANAM” 
(INTERNAL) AND VATHA MEGA NARAYANA ENNAI”” (EXTERNAL) IN THE 
TREATMENT OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS)  
Principal Investigator: Dr.T.R.Nishitha 
 
FORM  -III   CLINICAL ASSESSMENT DURING & AFTER TRIAL 
 
1. OP/ IP NO: …………      2. SL. NO: ……… 
3.NAME: …………………              4. AGE/SEX: ……… 
5. DATE OF RECRUITMENT: …… 
 
GENERAL EXAMINATION: 
1. Body weight [Kg]     
2. Height [cms] 
3. Body Temperature [0F] 
4. Blood Pressure (mm/Hg) 
5. Pulse Rate /min 
6. Heart Rate / min.  
7. Respiratory Rate /min.   
    Yes            No   
8. Pallor    :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   : 
13. Lymphadenopathy     :  
14. Jugular venous pulsation  :   
 
SYSTEMIC EXAMINATION:         Normal       Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Uro-genital system     
6.  Endocrine system        
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SIDDHA SYSTEM OF EXAMINATION  
1. THEGI (TYPE OF BODY CONSTITUTION): 
1. Vaathaudal    3. Kabaudal 
2. Pithaudal    4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji    3. Paalai   
2. Mullai    4. Neithal 
5. Marutham 
3. KAALAM: 
1. Kaarkaalam    4. Pinpanikaalam 
2. Koothirkaalam    5. Ilavenilkaalam 
3. Munpanikaalam   6. Muthuvenilkaalam 
4. GUNAM: 
1. Sathuvam    2. Rasogunam 
3. Thamogunam 
 
5.PORIPULANGAL(SENSORY ORGANS): 
 1
st
 
day 
8
th
 
day 
15
th
 
day 
22
nd 
day 
29
th
 
day 
36
th
 
day  
43
rd
 
Day 
49
th
 
day 
Mei (skin)         
Vaai(tongue)         
Kan (eye)         
Mooku(nose)         
Sevi (ear)         
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6.KANMENDRIYAM(MOTOR ORGANS): 
 1
st
  
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Kai(upperlimb)         
Kaal(lowerlimb)         
Vaai(speech)         
Eruvai 
(excretory 
organ) 
        
Karuvai 
(reproductive 
organs) 
        
 
7.KOSANGAL (SHEATH):          
 1
st
  
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
AnnamayaK
osam 
        
Pranamaya
kosam 
        
Manomayak
osam 
        
Vignanamay
akosam 
        
Aanantham
ayakosam 
        
 
8.UYIR THATHUKKAL (THREE HUMOURS): 
A. VALI 
 1
st
 day 8
th
day 15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th 
day 
43
rd
   
day 
49
th
 
day 
Praanan         
Abaanan         
Viyaanan         
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Udhaanan         
Samaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
 
B) AZHAL 
 1
st
day 
8
th 
 day 
15
th
day 22
nd
day 29
th
day 36
th
day 
43
rd
day 49
th
day 
Analakam         
Prasakam          
Ranjakam         
Aalosakam 
        
Saathakam         
 
C. IYAM:             
 1
st
  
day 
8
th
 
day 
15
th
 
day 
22
nd 
 day 
29
th 
day 
36
th 
day 
43
rd
  
day 
49
th
 
day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam          
Santhigam          
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9.SEVEN UDAL DHATHUS: (7 SOMATIC COMPONENTS) 
 1
st
  
day 
8
th 
day 
15
th 
day 
22
nd
 
day 
29
th 
day 
36
th 
 
day 
43
rd
 
day 
49
th
  
day 
Saaram         
Senneer         
Oon         
Kozhuppu         
Enbu         
Moolai         
Sukkilam / 
Suronitham 
        
 
ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION]  
I. NAADI: [PULSE PERCEPTION] 
II. SPARISAM: 
1
st
 Day 8
th
 Day 15
th
 
Day 
22
nd 
day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
        
III. NAA:[TONGUE] 
1
st
 Day 8
th
 Day 15
th
 
Day 
22
nd 
Day 
29
th
 
Day 
36
th 
Day 
43
rd
 
Day 
49
th
 
Day 
        
 
VI.NIRAM: [COMPLEXION]   
1. Vaatham                                              3. Kabam 
2. Pitham 
 
1
st
 Day 8
th 
day
 
15
th
day 22
nd
day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
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V.MOZHI: [VOICE] 
1. High Pitched                                     2. Low Pitched 
3. Medium Pitched 
VI.VIZHI: [EYES]  
1
st
 Day 8
th
 Day 15
th
 
Day 
22
th
 
Day 
29
th
 
Day 
36
th
 
Day 
43
rd
 
Day 
49
th
 
Day 
        
VII. MALAM: [BOWEL HABITS / STOOLS] 
     Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
VIII. MOOTHIRAM [URINE EXAMINATION]  
Neerkkuri Before treatment After treatment 
Niram 
 
  
Manam   
Edai   
Nurai   
Enjal   
 
NEIKURI Before treatment After  treatment 
Aravu (Serpentine fashion)   
Aazhi (Annular/Ringed 
fashion) 
  
Muthu (Pearl beaded 
fashion) 
  
Kalappu (Mixed fashion)   
Other fashion   
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 Outcome: 
I. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
Grade0   :   No Pain 
Grade  1-3   :   Mild pain 
Grade 4-6   :   Moderate pain 
Grade 7-10  :   Severe pain 
 
II. RESTRICTED MOVEMENT ASSESSMENT SCALE:GRADATION OF 
MOVEMENTS 
Grade 1  –  Able to perform normal duties 
Grade II  –  Moderate Restriction – Self care is possible 
Grade III  –  Marked restriction – Limited self care /some assistance required. 
Grade IV  – Confined to bed or wheel chair 
 (Ref: Clinical manual for nursing practice (National Institute of Health Warren 
Grant Magnuson Clinical Centre) 
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Date:      
Station: 
Signature of the Investigator:  
 
Signature of the Lecturer:                                                              Signature of HOD 
 
 
 
 
 
 
 
 
 
 
 
1
st
 
day 
8
th
 day 15
th
 day 
22
nd
 
day 
 
29
th
 
day 
 
36
th
 
day 
 
43
rd
 
day 
 
49
th
 
day 
Date         
Pain         
Tender 
Ness 
    
    
 swelling         
Morning 
Stiffness 
   
    
 
Restriction 
Of 
movements 
   
    
 
Duration 
of relief 
   
    
 
Other 
clinical 
features. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG“VAATHA 
CHOORANAM” (INTERNAL) AND “VATHA MEGA NARAYANA ENNAI” (EXTERNAL) IN 
THE TREATMENT OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS) 
Principal Investigator: Dr.T.R.Nishitha 
1. SERIAL NO:       
2. OP /IP NO:                 
3. NAME:             
4. AGE/GENDER: 
FORM-IV - LABORATORY INVESTIGATIONS 
 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE TMT 
( DATE) 
AFTER TMT 
(DATE) 
Hb (gm/dl) 
M:12-15 
W:11.5-12 
  
T.WBC (cells/cu.mm) 4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 
T.RBC (million cells / cu.mm) 
 
M:4.0-5.5 
W:3.5-4.5 
 
 
 
 
ESR (mm/hour) ½ hr. 
M:6-12 
W:7-18 
  
  1 hr.  
 
 
Blood glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Random 80-120   
RFT (mg/dl) 
Blood urea 16-50   
Serum Creatinine 0.6-1.2   
LFT (mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-1.2   
Indirect bilirubin 0.2-0.7   
SGOT 0-40   
SGPT 0-35   
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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Alkaline 
phosphatase 
80-290   
 
 
 
 
 
ASO Titer 
 
 
 
 
RA Factor   
C-Reactive  Protein   
 
 
 
 
 
LIPID 
PROFILE 
 
 
 
 
 
 
 
Serum total 
cholesterol 
 
150-225mg/dl 
 
 
 
 
 
 
Serum triglycerides 
 
 
30-63mg/dl 
 
 
 
 
 
 
HDL Cholesterol 
 
 
<130mg/dl 
 
 
 
 
 
 
LDL Cholesterol 
 
 
<40mg/dl 
 
 
 
 
 
 
 
 
VLDL Cholesterol 
 
<160mg/dl 
 
 
 
 
 
 
B. URINE ANALYSIS 
 
 
 
 
 
 
Date:          
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         Signature of the HOD 
 
URINE INVESTIGATION BEFORE TMT( DATE) AFTER TMT ( DATE) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VAATHA 
CHOORANAM” (INTERNAL) AND “VAATHA MEGA NARAYANA ENNAI” (EXTERNAL) IN 
THE TREATMENT OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS )  
Name of Principal Investigator: Dr.T.R.Nishitha      
 
FORM-VI – CONSENT FORM 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand 
that I have the   right to withdraw from the study at any time without in any way it 
affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
individual has given consent freely.”                                                   
 
 
Date: 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)   
      
  
 
 
 
 
 
 
Left thumb Impression of the Participant 
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FORM –VI ´ôÒ¾ø ÀÊÅõ 
 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
¿¡ý ÅÇ¢ «Æø ¸£ø Å¡Ô ±ýÛõ §¿¡Â¢ý ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ 
Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌôÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
§¾¾¢:                                      ¨¸¦Â¡ôÀõ: 
 
þ¼õ:                 ¦ÀÂ÷:   
 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ  þó¾  ÁÕòÐÅ  ¬öÅ¢ý  ¸¡Ã½ò¨¾Ôõ,  ÁÕó¾¢ý ¾ý¨Á  
ÁüÚõÁÕòÐÅ  ÅÆ¢Ó¨È  ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ  ±ÉÐ  ¯¼ø  þÂì¸ò¨¾ì  
¸ñ¸¡½¢ì¸×õ, «¾¨Éô  À¡Ð¸¡ì¸×õ  ÀÂýÀÎõÁÕòÐÅ  ¬ö×ìÜ¼  
ÀÃ¢§º¡¾¨É¸û  ÀüÈ¢  ¾¢Õô¾¢ «Ç¢ìÌõ  Å¨¸Â¢ø  ¬ö×  ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì  
ÜÈôÀð¼Ð. 
¿¡ý  þó¾ÁÕòÐÅ  ¬öÅ¢ý  §À¡Ð, ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõþó¾  
¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ  ¦¸¡ûÙõ  ¯Ã¢¨Á¨Âò ¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
           ¿¡ý  ±ýÛ¨¼Â  Í¾ó¾¢ÃÁ¡¸ò  §¾÷×  ¦ºöÔõ  ¯Ã¢¨Á¨Âì  
¦¸¡ñÎ ÅÇ¢«Æø ¸£ø Å¡Ô §¿¡öì¸¡É Å¡¾ ÝÃ½õ(¯û ÁÕóÐ) ÁüÚõ 
Å¡¾§Á¸¿¡Ã¡Â½±ñ¦½ö(¦ÅÇ¢ ÁÕóÐ) ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò  ¾¢È¨Éì  
¸ñ¼È¢Ôõ  ÁÕòÐÅ  ¬öÅ¢üÌ  ±ý¨É  ¯ðÀÎò¾ ´ôÒ¾ø  «Ç¢ì¸¢§Èý. 
 
 
§¾¾¢:            ¨¸¦Â¡ôÀõ: 
þ¼õ:          ¦ÀÂ÷:   
        º¡ðº¢ì¸¡Ã÷¨¸¦Â¡ôÀõ: 
         ¦ÀÂ÷:                          
          ¯È×Ó¨È:  
 
Å¢Ã¢×¨ÃÂ¡Ç¡÷ ¨¸¦Â¡ôÀõ:Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VATHA CHOORANAM” 
(INTERNAL) AND “VATHA  MEGA  NARAYANA  ENNAI”(EXTERNAL) IN THE 
TREATMENT OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS  
Name of Principal Investigator: Dr.T.R.Nishitha      
 
FORM VII -WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE:  
2. OP / IP NO:   
3. NAME:   
4. AGE:  
5. GENDER: 
6. DATE OF TRIAL COMMENCEMENT:  
7. DATE OF WITHDRAWAL FROM TRIAL:  
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                            Yes/No 
(If YES, give the details of adverse reaction in Form VII -B – Adverse      
Reaction Form / Pharmaco Vigilance Form) 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VATHA CHOORANAM” 
(INTERNAL) AND “VATHA MEGA NARAYANA ENNAI”(EXTERNAL) IN THE TREATMENT 
OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS )  
 
Name of Principal Investigator:Dr.T.R.Nishitha     
 
FORM VII - A – ADVERSE REACTION FORM / PHARMACO VIGILANCE FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
 
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHARHOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUG “VATHA 
CHOORANAM”(INTERNAL) AND “VATHA MEGA NARAYANA ENNAI”(EXTERNAL) IN 
THE TREATMENT OF “VALI AZHAL KEEL VAYU”(RHEUMATOID ARTHRITIS)  
FORM V– PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.T.R.Nishitha 
Name of the institute: National Institute of Siddha, 
Tambaram Sanatorium, 
Chennai-47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL 
TRIAL. 
 I,:Dr.T.R.Nishitha , studying M.D(Siddha) at National Institute of Siddha, Tambaram 
Sanatorium is doing a trial on  “VALI AHZAL KEEL VAYU” (Rheumatoid arthritis). It is a common 
degenerative disease, occurring throughout the world. In this regard, I am in a need to ask you few 
questions. I will maintain confidentiality of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is involved by taking part 
in this study. Taking part in this study is voluntary. No compensation will be paid to you for taking  
part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. There is no 
specific benefit for you if you take part in the study. However, taking part in the study may be of 
benefit to the community, as it may help us to understand the problem of defaulters and potential 
solutions. 
             If you agree to be a participant in this study, you will be included in the study primarily by 
signing the consent form and then you will be given the internal medicine“ VATHA 
CHOORANAM”(Internal medicine) 2gm, twice a day, for 48 days and “VATHA MEGA NARAYANA 
ENNAI(External medicine). If you wish to stay in the In Patient ward Treatment will be provided to 
you assuring that you will not be definitely hurt in any course of treatment. 
 The information I am collecting in this study will remain between you and the principal 
investigator (myself). I will ask you few questions through a questionnaire. I will not write your name 
on this form. Ur name won’t be mentioned in the lab investigation form instead a code will be used. 
The questionnaire will take approximately 20 minutes of your time. 
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If you want to know more about this study before taking part, you can ask me all the 
questions you want or contact Dr.T.R.Nishitha, PG Scholar cum principal investigator of this study,  
National Institute of Siddha, Chennai-47. You can also contact the Member-secretary of Ethics 
committee, National Institute Siddha, Chennai 600047, Tel.No: 91-44-22380789, for rights and 
participation in the study.  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND CLINICAL STUDY OF SIDDHA DRUGS “VAATHA 
CHOORANAM” (INTERNAL) AND “VATHA MEGA NARAYANA ENNAI” (EXTERNAL) IN 
THE TREATMENT OF   “VALI AZHAL KEEL VAYU” (RHEUMATOID ARTHRITIS )  
Principal Investigator: Dr.T.R.Nishitha 
 
§º÷ì¸ ÜÊÂ ¯½×¸û: 
¸¡ö¸û: 
ÓÕí¨¸À¢ïÍ, 
«Å¨ÃÀ¢ïÍ, 
À¢Ãñ¨¼, 
¸¡Ãð, 
À£ðåð. 
¸£¨Ã¸û: 
¸Ã¢º¡¨Ä, 
¦À¡ýÉ¡í¸ñ½¢, 
Á½ò¾ì¸¡Ç¢,              
ÓÕí¨¸¸£¨Ã, 
Àº¨Ä¸£¨ Ã, 
º¢Ú¸£¨ Ã,                 
¸È¢§ÅôÀ¢¨Ä,  
      ¦¸¡ò¾ÁøÄ¢. 
Ò¾¢É¡. 
ÀÆí¸û: 
Á¡Ð¨Ç, 
¬ôÀ¢û, 
Å¡¨Æ, 
§ÀÃ£î¨º, 
«ò¾¢,               
¾¢Ã¡ð¨º, 
¦¸¡öÂ¡                
¿¡Åø, 
ºô§À¡ð¼¡, 
¯Ä÷ ¾¢Ã¡ð¨º. 
Page 205 
 
¾¡É¢Âí¸û 
Ó¨Ç ¸ðÊÂ ÀÂ¢÷ Å¨¸¸û,  
§º¡Â¡À£ýŠ, 
 ¦Åó¾Âõ. 
«¨ºÅõ: 
¦ÅûÇ¡ðÎ¸È¢ ®Ãø, 
±ÖõÒÁˆ¨ƒ, 
ÁüÈ¨Å: 
À¨É ¦ÅøÄõ 
À¡ø 
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û:  
§¸¡Æ¢ì¸È¢, Á£ý, ¿ñÎ, ¸ÕÅ¡Î, 
§Å÷ì¸¼¨Ä, 
±ûÙ, 
ÀôÀ¡Ç¢, 
«ýÉ¡º¢, 
¿ø¦Äñ¦½ö, 
ÒÇ¢ôÒ ¦À¡Õû¸û, 
±ÖÁ¢î¨º, 
¾ì¸¡Ç¢, 
ÒÇ¢ôÒ ¾Â¢÷ §Á¡÷, 
°Ú¸¡ö, 
¦Àñ§À¡¸õ,Ò¨¸Â¢¨Ä , 
¦ÅüÈ¢¨Ä,À¡ìÌ , 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2MMT Code: 
 
 
RBC  (×106 µl) 5.2 
WBC (×10 3 µl) 9.7 
PLT (×10 3 µl) 732 
HGB (g/dl) 12.5 
MCH (pg) 15.5 
MCV(fl) 59.1 
Neutrophils 103/mm3 1.9 
Eosinophils (%) 1.7 
Basophils (%) 0 
Lymph (%) 87.3 
Mon (%) 5.8 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1HMT Code: 
 
 
 
 
RBC  (×106 µl) 4.1 
WBC (×10 3 µl) 13.4 
PLT (×10 3 µl) 621 
HGB (g/dl) 14.4 
MCH (pg) 20.6 
MCV(fl) 64.6 
Neutrophils 103/mm3 1.8 
Eosinophils (%) 1.9 
Basophils (%) 0 
Lymph (%) 78.3 
Mon (%) 4.8 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1HMH Code: 
 
 
RBC  (×106 µl) 5.2 
WBC (×10 3 µl) 11.3 
PLT (×10 3 µl) 538 
HGB (g/dl) 14.8 
MCH (pg) 21 
MCV(fl) 60.4 
Neutrophils 103/mm3 2.5 
Eosinophils (%) 1.2 
Basophils (%) 0 
Lymph (%) 87.4 
Mon (%) 3.2 
   
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2LFH Code: 
 
 
 
RBC  (×106 µl) 5.8 
WBC (×10 3 µl) 12.2 
PLT (×10 3 µl) 519 
HGB (g/dl) 15.7 
MCH (pg) 21.3 
MCV(fl) 66.8 
Neutrophils 103/mm3 3.1 
Eosinophils (%) 1.1 
Basophils (%) 0 
Lymph (%) 67.3 
Mon (%) 3.3 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1HMB Code: 
 
 
RBC  (×106 µl) 4.7 
WBC (×10 3 µl) 7.3 
PLT (×10 3 µl) 656 
HGB (g/dl) 15.5 
MCH (pg) 22.2 
MCV(fl) 62.9 
Neutrophils 103/mm3 3.1 
Eosinophils (%) 1.4 
Basophils (%) 0 
Lymph (%) 66.2 
Mon (%) 4.4 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2LFT Code: 
 
 
 
RBC  (×106 µl) 4.6 
WBC (×10 3 µl) 8.3 
PLT (×10 3 µl) 745 
HGB (g/dl) 13.9 
MCH (pg) 20.5 
MCV(fl) 58 
Neutrophils 103/mm3 3.2 
Eosinophils (%) 1.3 
Basophils (%) 0 
Lymph (%) 67.6 
Mon (%) 2.3 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2HFT Code: 
 
 
 
 
RBC  (×106 µl) 2.9 
WBC (×10 3 µl) 9.4 
PLT (×10 3 µl) 863 
HGB (g/dl) 12.5 
MCH (pg) 16.4 
MCV(fl) 72.4 
Neutrophils 103/mm3 4 
Eosinophils (%) 1.5 
Basophils (%) 0 
Lymph (%) 75.5 
Mon (%) 3.1 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
Sample ID C2MFH Code: 
 
 
 
 
RBC  (×106 µl) 8.8 
WBC (×10 3 µl) 9.9 
PLT (×10 3 µl) 774 
HGB (g/dl) 12.2 
MCH (pg) 17.9 
MCV(fl) 58.8 
Neutrophils 103/mm3 2.4 
Eosinophils (%) 1.6 
Basophils (%) 1 
Lymph (%) 89.8 
Mon (%) 1.6 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2MFB Code: 
 
 
 
 
RBC  (×106 µl) 7.7 
WBC (×10 3 µl) 7.1 
PLT (×10 3 µl) 753 
HGB (g/dl) 14.3 
MCH (pg) 14.9 
MCV(fl) 74 
Neutrophils 103/mm3 1.6 
Eosinophils (%) 1.5 
Basophils (%) 0 
Lymph (%) 71.9 
Mon (%) 3.4 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1HMH Code: 
 
 
 
RBC  (×106 µl) 6.4 
WBC (×10 3 µl) 6.7 
PLT (×10 3 µl) 882 
HGB (g/dl) 8.5 
MCH (pg) 13.4 
MCV(fl) 55.5 
Neutrophils 103/mm3 1.7 
Eosinophils (%) 1.4 
Basophils (%) 0 
Lymph (%) 82.5 
Mon (%) 1.3 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2MFT Code: 
 
 
 
RBC  (×106 µl) 5.3 
WBC (×10 3 µl) 8 
PLT (×10 3 µl) 781 
HGB (g/dl) 12.6 
MCH (pg) 21.1 
MCV(fl) 70.6 
Neutrophils 103/mm3 2.6 
Eosinophils (%) 1.3 
Basophils (%) 0 
Lymph (%) 73.3 
Mon (%) 1.3 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2HMB Code: 
 
 
RBC  (×106 µl) 6.5 
WBC (×10 3 µl) 9.5 
PLT (×10 3 µl) 678 
HGB (g/dl) 14.6 
MCH (pg) 26.3 
MCV(fl) 60.4 
Neutrophils 103/mm3 3.1 
Eosinophils (%) 1.5 
Basophils (%) 1 
Lymph (%) 61.7 
Mon (%) 2.3 
 
 
 
  
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1HFB Code: 
 
 
RBC  (×106 µl) 5.9 
WBC (×10 3 µl) 7.3 
PLT (×10 3 µl) 955 
HGB (g/dl) 9.6 
MCH (pg) 17.2 
MCV(fl) 65.3 
Neutrophils 103/mm3 2.2 
Eosinophils (%) 1.3 
Basophils (%) 0 
Lymph (%) 78.7 
Mon (%) 1.7 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1MFT Code: 
 
 
 
RBC  (×106 µl) 5.4 
WBC (×10 3 µl) 15.2 
PLT (×10 3 µl) 946 
HGB (g/dl) 14.9 
MCH (pg) 17.1 
MCV(fl) 66.2 
Neutrophils 103/mm3 1.9 
Eosinophils (%) 1.7 
Basophils (%) 0 
Lymph (%) 89.8 
Mon (%) 5.8 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LMH Code: 
 
 
RBC  (×106 µl) 5.5 
WBC (×10 3 µl) 7.3 
PLT (×10 3 µl) 862 
HGB (g/dl) 12.5 
MCH (pg) 21.6 
MCV(fl) 52.1 
Neutrophils 103/mm3 1.8 
Eosinophils (%) 1.1 
Basophils (%) 1 
Lymph (%) 61.8 
Mon (%) 5.3 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LFH Code: 
 
 
 
RBC  (×106 µl) 5.4 
WBC (×10 3 µl) 13.6 
PLT (×10 3 µl) 655 
HGB (g/dl) 12.1 
MCH (pg) 22.2 
MCV(fl) 60.3 
Neutrophils 103/mm3 3.3 
Eosinophils (%) 1.5 
Basophils (%) 0 
Lymph (%) 68.9 
Mon (%) 3.6 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2MMH Code: 
 
 
 
RBC  (×106 µl) 6.4 
WBC (×10 3 µl) 9.4 
PLT (×10 3 µl) 885 
HGB (g/dl) 15.2 
MCH (pg) 23.6 
MCV(fl) 52.8 
Neutrophils 103/mm3 2.9 
Eosinophils (%) 1.5 
Basophils (%) 0 
Lymph (%) 62.4 
Mon (%) 4.7 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2MMB Code: 
 
RBC  (×106 µl) 5.3 
WBC (×10 3 µl) 7.5 
PLT (×10 3 µl) 692 
HGB (g/dl) 14.5 
MCH (pg) 20.3 
MCV(fl) 50.4 
Neutrophils 103/mm3 2.7 
Eosinophils (%) 1.7 
Basophils (%) 0 
Lymph (%) 60.5 
Mon (%) 3.3 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2HFB Code: 
 
 
 
RBC  (×106 µl) 6.2 
WBC (×10 3 µl) 10.2 
PLT (×10 3 µl) 525 
HGB (g/dl) 16.3 
MCH (pg) 20.7 
MCV(fl) 65 
Neutrophils 103/mm3 2.9 
Eosinophils (%) 1.9 
Basophils (%) 0 
Lymph (%) 96.9 
Mon (%) 2.3 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2LMH Code: 
 
 
 
RBC  (×106 µl) 6.2 
WBC (×10 3 µl) 10.3 
PLT (×10 3 µl) 738 
HGB (g/dl) 14.7 
MCH (pg) 23.4 
MCV(fl) 55.2 
Neutrophils 103/mm3 2.2 
Eosinophils (%) 1.9 
Basophils (%) 1 
Lymph (%) 85.3 
Mon (%) 4.2 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2HMT Code: 
 
 
 
RBC  (×106 µl) 7.1 
WBC (×10 3 µl) 8.5 
PLT (×10 3 µl) 836 
HGB (g/dl) 12.4 
MCH (pg) 18.8 
MCV(fl) 50.7 
Neutrophils 103/mm3 1.7 
Eosinophils (%) 1.4 
Basophils (%) 0 
Lymph (%) 73.2 
Mon (%) 3.1 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2LMT Code: 
 
 
 
 
RBC  (×106 µl) 6.2 
WBC (×10 3 µl) 12.2 
PLT (×10 3 µl) 943 
HGB (g/dl) 15.5 
MCH (pg) 16.9 
MCV(fl) 52.8 
Neutrophils 103/mm3 3.2 
Eosinophils (%) 1.3 
Basophils (%) 0 
Lymph (%) 86.2 
Mon (%) 4.1 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LFH Code: 
 
 
RBC  (×106 µl) 7.6 
WBC (×10 3 µl) 9.5 
PLT (×10 3 µl) 856 
HGB (g/dl) 9.5 
MCH (pg) 19.9 
MCV(fl) 51.2 
Neutrophils 103/mm3 2.7 
Eosinophils (%) 1.2 
Basophils (%) 1 
Lymph (%) 86.3 
Mon (%) 5.4 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LMT Code: 
 
 
RBC  (×106 µl) 7.7 
WBC (×10 3 µl) 8.4 
PLT (×10 3 µl) 926 
HGB (g/dl) 14.1 
MCH (pg) 19.1 
MCV(fl) 67.7 
Neutrophils 103/mm3 1.1 
Eosinophils (%) 1.1 
Basophils (%) 0 
Lymph (%) 67.1 
Mon (%) 5.5 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1MMB Code: 
 
RBC  (×106 µl) 7.9 
WBC (×10 3 µl) 8.1 
PLT (×10 3 µl) 623 
HGB (g/dl) 11.8 
MCH (pg) 20.8 
MCV(fl) 68.1 
Neutrophils 103/mm3 1.2 
Eosinophils (%) 1.1 
Basophils (%) 0 
Lymph (%) 75.1 
Mon (%) 4.4 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2HFH Code: 
 
RBC  (×106 µl) 5.4 
WBC (×10 3 µl) 8.4 
PLT (×10 3 µl) 732 
HGB (g/dl) 9.7 
MCH (pg) 20.6 
MCV(fl) 63.2 
Neutrophils 103/mm3 3.1 
Eosinophils (%) 1.2 
Basophils (%) 0 
Lymph (%) 84.2 
Mon (%) 3.5 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1LFB Code: 
 
RBC  (×106 µl) 5.3 
WBC (×10 3 µl) 12.1 
PLT (×10 3 µl) 512 
HGB (g/dl) 15.4 
MCH (pg) 17.2 
MCV(fl) 72.5 
Neutrophils 103/mm3 2.7 
Eosinophils (%) 1.9 
Basophils (%) 1 
Lymph (%) 63.3 
Mon (%) 4.2 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1LMB Code: 
 
RBC  (×106 µl) 6.2 
WBC (×10 3 µl) 15.2 
PLT (×10 3 µl) 631 
HGB (g/dl) 13.5 
MCH (pg) 18.7 
MCV(fl) 67.9 
Neutrophils 103/mm3 2.8 
Eosinophils (%) 1.8 
Basophils (%) 0 
Lymph (%) 64.4 
Mon (%) 2.8 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1HFH Code: 
 
 
RBC  (×106 µl) 5.5 
WBC (×10 3 µl) 11.1 
PLT (×10 3 µl) 772 
HGB (g/dl) 12.4 
MCH (pg) 21.7 
MCV(fl) 52.6 
Neutrophils 103/mm3 2.9 
Eosinophils (%) 1.7 
Basophils (%) 0 
Lymph (%) 78.7 
Mon (%) 5.6 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C2HMH Code: 
 
RBC  (×106 µl) 7.4 
WBC (×10 3 µl) 15.5 
PLT (×10 3 µl) 848 
HGB (g/dl) 14.1 
MCH (pg) 17.9 
MCV(fl) 68.3 
Neutrophils 103/mm3 2.7 
Eosinophils (%) 1.5 
Basophils (%) 0 
Lymph (%) 86.9 
Mon (%) 5.5 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1HFT Code: 
 
 
 
RBC  (×106 µl) 6.3 
WBC (×10 3 µl) 10.4 
PLT (×10 3 µl) 932 
HGB (g/dl) 9 
MCH (pg) 19.2 
MCV(fl) 54.5 
Neutrophils 103/mm3 2.5 
Eosinophils (%) 1.4 
Basophils (%) 1 
Lymph (%) 97.9 
Mon (%) 3.3 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
 
Sample ID C1LFT Code: 
 
 
 
RBC  (×106 µl) 5.2 
WBC (×10 3 µl) 8.7 
PLT (×10 3 µl) 748 
HGB (g/dl) 14 
MCH (pg) 21.3 
MCV(fl) 52.5 
Neutrophils 103/mm3 1.7 
Eosinophils (%) 1.3 
Basophils (%) 0 
Lymph (%) 88.2 
Mon (%) 2.4 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1MFH Code: 
 
 
RBC  (×106 µl) 6.8 
WBC (×10 3 µl) 8.7 
PLT (×10 3 µl) 622 
HGB (g/dl) 14.9 
MCH (pg) 17.3 
MCV(fl) 68.3 
Neutrophils 103/mm3 1.5 
Eosinophils (%) 1.8 
Basophils (%) 1 
Lymph (%) 82.2 
Mon (%) 3.5 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2LMB Code: 
 
 
 
RBC  (×106 µl) 5.6 
WBC (×10 3 µl) 13.6 
PLT (×10 3 µl) 728 
HGB (g/dl) 16.6 
MCH (pg) 19.2 
MCV(fl) 63.2 
Neutrophils 103/mm3 1.6 
Eosinophils (%) 1.4 
Basophils (%) 0 
Lymph (%) 81.7 
Mon (%) 2.4 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID 
 
C2HFB 
 
Code:  
 
 
BUN (mg/dl) 12.2 
Serum Creatinine (mg/dl) 1 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 132 
SGPT (IU/ml) 41 
Total cholesterol (mg/dl) 134.9 
HDL (mg/dl) 55 
LDL (mg/dl) 52 
VLDL (mg/dl) 27.9 
TG (mg/dl) 21 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1MMT Code: 
 
 
BUN (mg/dl) 20 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 120 
SGPT (IU/ml) 29 
Total cholesterol (mg/dl) 119.8 
HDL (mg/dl) 63 
LDL (mg/dl) 38 
VLDL (mg/dl) 18.8 
TG (mg/dl) 28 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2MMB Code: 
 
 
BUN (mg/dl) 14.5 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 147 
SGPT (IU/ml) 42 
Total cholesterol (mg/dl) 142.7 
HDL (mg/dl) 74 
LDL (mg/dl) 43 
VLDL (mg/dl) 25.7 
TG (mg/dl) 31 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LMT Code: 
 
 
BUN (mg/dl) 15.3 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 178 
SGPT (IU/ml) 28 
Total cholesterol (mg/dl) 110.2 
HDL (mg/dl) 55 
LDL (mg/dl) 45 
VLDL (mg/dl) 10.2 
TG (mg/dl) 14 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2HFT Code: 
 
 
BUN (mg/dl) 16.5 
Serum Creatinine (mg/dl) 0.6 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 197 
SGPT (IU/ml) 56 
Total cholesterol (mg/dl) 123.3 
HDL (mg/dl) 57 
LDL (mg/dl) 41 
VLDL (mg/dl) 25.3 
TG (mg/dl) 49 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2LMB Code: 
 
 
BUN (mg/dl) 19.5 
Serum Creatinine (mg/dl) 1.1 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 156 
SGPT (IU/ml) 64 
Total cholesterol (mg/dl) 149.1 
HDL (mg/dl) 74 
LDL (mg/dl) 54 
VLDL (mg/dl) 21.1 
TG (mg/dl) 53 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1MMH Code: 
 
BUN (mg/dl) 15.2 
Serum Creatinine (mg/dl) 1.1 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 123 
SGPT (IU/ml) 24 
Total cholesterol (mg/dl) 179.3 
HDL (mg/dl) 73 
LDL (mg/dl) 82 
VLDL (mg/dl) 24.3 
TG (mg/dl) 68 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
Sample ID C2HFH Code: 
 
BUN (mg/dl) 18.4 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 94 
SGPT (IU/ml) 42 
Total cholesterol (mg/dl) 165.2 
HDL (mg/dl) 67 
LDL (mg/dl) 82 
VLDL (mg/dl) 16.2 
TG (mg/dl) 53 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C2HMB Code: 
 
 
BUN (mg/dl) 16.3 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 118 
SGPT (IU/ml) 34 
Total cholesterol (mg/dl) 174.1 
HDL (mg/dl) 86 
LDL (mg/dl) 73 
VLDL (mg/dl) 15.1 
TG (mg/dl) 49 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LMB Code: 
 
 
BUN (mg/dl) 16.5 
Serum Creatinine (mg/dl) 0.9 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 186 
SGPT (IU/ml) 54 
Total cholesterol (mg/dl) 150.2 
HDL (mg/dl) 78 
LDL (mg/dl) 61 
VLDL (mg/dl) 11.2 
TG (mg/dl) 34 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LMH Code: 
 
 
BUN (mg/dl) 20.1 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 125 
SGPT (IU/ml) 55 
Total cholesterol (mg/dl) 153.1 
HDL (mg/dl) 64 
LDL (mg/dl) 64 
VLDL (mg/dl) 25.1 
TG (mg/dl) 61 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1LFT Code: 
 
BUN (mg/dl) 17.4 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 199 
SGPT (IU/ml) 73 
Total cholesterol (mg/dl) 169.4 
HDL (mg/dl) 73 
LDL (mg/dl) 76 
VLDL (mg/dl) 20.4 
TG (mg/dl) 74 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1HMT Code: 
 
 
BUN (mg/dl) 20 
Serum Creatinine (mg/dl) 0.6 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 154 
SGPT (IU/ml) 21 
Total cholesterol (mg/dl) 133.5 
HDL (mg/dl) 62 
LDL (mg/dl) 58 
VLDL (mg/dl) 13.5 
TG (mg/dl) 47 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
Sample ID C1MMB Code: 
 
BUN (mg/dl) 15.5 
Serum Creatinine (mg/dl) 1.2 
Total Bilirubin (mg/dl) 0.5 
SGOT (IU/ml) 90 
SGPT (IU/ml) 31 
Total cholesterol (mg/dl) 161.6 
HDL (mg/dl) 72 
LDL (mg/dl) 60 
VLDL (mg/dl) 29.6 
TG (mg/dl) 54 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1HFB Code: 
 
BUN (mg/dl) 13.9 
Serum Creatinine (mg/dl) 0.9 
Total Bilirubin (mg/dl) 0.9 
SGOT (IU/ml) 132 
SGPT (IU/ml) 40 
Total cholesterol (mg/dl) 161.8 
HDL (mg/dl) 68 
LDL (mg/dl) 70 
VLDL (mg/dl) 23.8 
TG (mg/dl) 45 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
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Sample ID C1HFT Code: 
 
BUN (mg/dl) 20 
Serum Creatinine (mg/dl) 0.6 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 140 
SGPT (IU/ml) 27 
Total cholesterol (mg/dl) 176.8 
HDL (mg/dl) 67 
LDL (mg/dl) 85 
VLDL (mg/dl) 24.8 
TG (mg/dl) 56 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Source: National Institute of Siddha                                                                   Purpose: Academic Research 
Date:    22/05/2017 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
 
Sample ID C1HMH Code: 
 
 
BUN (mg/dl) 13.4 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 211 
SGPT (IU/ml) 86 
Total cholesterol (mg/dl) 157.4 
HDL (mg/dl) 75 
LDL (mg/dl) 64 
VLDL (mg/dl) 18.4 
TG (mg/dl) 52 
              Noble Research Solutions     
We Trust in Quality and Ethics 
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Sample ID C1HMB Code: 
 
 
BUN (mg/dl) 16.1 
Serum Creatinine (mg/dl) 0.5 
Total Bilirubin (mg/dl) 0.8 
SGOT (IU/ml) 121 
SGPT (IU/ml) 53 
Total cholesterol (mg/dl) 124.1 
HDL (mg/dl) 66 
LDL (mg/dl) 43 
VLDL (mg/dl) 15.1 
TG (mg/dl) 43 
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Sample ID C2MMT Code: 
 
 
BUN (mg/dl) 18.4 
Serum Creatinine (mg/dl) 1.1 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 90 
SGPT (IU/ml) 28 
Total cholesterol (mg/dl) 130.3 
HDL (mg/dl) 62 
LDL (mg/dl) 52 
VLDL (mg/dl) 16.3 
TG (mg/dl) 58 
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Sample ID C2MMH Code: 
 
 
BUN (mg/dl) 12.6 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.6 
SGOT (IU/ml) 83 
SGPT (IU/ml) 32 
Total cholesterol (mg/dl) 121.5 
HDL (mg/dl) 64 
LDL (mg/dl) 46 
VLDL (mg/dl) 11.5 
TG (mg/dl) 54 
              Noble Research Solutions     
We Trust in Quality and Ethics 
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Sample ID C2LMT Code: 
 
 
BUN (mg/dl) 17.2 
Serum Creatinine (mg/dl) 1 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 130 
SGPT (IU/ml) 25 
Total cholesterol (mg/dl) 160.2 
HDL (mg/dl) 65 
LDL (mg/dl) 74 
VLDL (mg/dl) 21.2 
TG (mg/dl) 22 
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Sample ID C1LFH Code: 
 
 
BUN (mg/dl) 18.3 
Serum Creatinine (mg/dl) 0.5 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 128 
SGPT (IU/ml) 45 
Total cholesterol (mg/dl) 173.1 
HDL (mg/dl) 55 
LDL (mg/dl) 83 
VLDL (mg/dl) 35.1 
TG (mg/dl) 33 
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Sample ID C2HMH Code: 
 
 
BUN (mg/dl) 20.1 
Serum Creatinine (mg/dl) 1 
Total Bilirubin (mg/dl) 0.1 
SGOT (IU/ml) 155 
SGPT (IU/ml) 71 
Total cholesterol (mg/dl) 172.7 
HDL (mg/dl) 51 
LDL (mg/dl) 97 
VLDL (mg/dl) 24.7 
TG (mg/dl) 28 
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Sample ID C2HMT Code: 
 
BUN (mg/dl) 12.3 
Serum Creatinine (mg/dl) 0.6 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 118 
SGPT (IU/ml) 40 
Total cholesterol (mg/dl) 140.8 
HDL (mg/dl) 64 
LDL (mg/dl) 66 
VLDL (mg/dl) 10.8 
TG (mg/dl) 37 
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Sample ID C2LFH Code: 
 
 
BUN (mg/dl) 13.6 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.6 
SGOT (IU/ml) 82 
SGPT (IU/ml) 29 
Total cholesterol (mg/dl) 122.1 
HDL (mg/dl) 56 
LDL (mg/dl) 52 
VLDL (mg/dl) 14.1 
TG (mg/dl) 32 
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Sample ID C2LMH Code: 
 
 
BUN (mg/dl) 10.2 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 70 
SGPT (IU/ml) 23 
Total cholesterol (mg/dl) 169.1 
HDL (mg/dl) 59 
LDL (mg/dl) 79 
VLDL (mg/dl) 31.1 
TG (mg/dl) 46 
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Sample ID C1HFH Code: 
 
 
BUN (mg/dl) 15.2 
Serum Creatinine (mg/dl) 0.6 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 80 
SGPT (IU/ml) 63 
Total cholesterol (mg/dl) 175.1 
HDL (mg/dl) 55 
LDL (mg/dl) 98 
VLDL (mg/dl) 22.1 
TG (mg/dl) 55 
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Sample ID C1MFT Code: 
 
BUN (mg/dl) 12.3 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 161 
SGPT (IU/ml) 64 
Total cholesterol (mg/dl) 144.8 
HDL (mg/dl) 71 
LDL (mg/dl) 62 
VLDL (mg/dl) 11.8 
TG (mg/dl) 44 
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Services offered: Standardization and Characterization of AYUSH formulations 
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Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
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Sample ID C1MFB Code: 
 
 
BUN (mg/dl) 13.4 
Serum Creatinine (mg/dl) 1 
Total Bilirubin (mg/dl) 0.4 
SGOT (IU/ml) 88 
SGPT (IU/ml) 29 
Total cholesterol (mg/dl) 140 
HDL (mg/dl) 62 
LDL (mg/dl) 52 
VLDL (mg/dl) 26 
TG (mg/dl) 29 
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Sample ID C2MFH Code: 
 
BUN (mg/dl) 12.3 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 95 
SGPT (IU/ml) 30 
Total cholesterol (mg/dl) 136.4 
HDL (mg/dl) 52 
LDL (mg/dl) 64 
VLDL (mg/dl) 20.4 
TG (mg/dl) 33 
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Sample ID C2LFB Code: 
 
BUN (mg/dl) 13.2 
Serum Creatinine (mg/dl) 1 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 158 
SGPT (IU/ml) 55 
Total cholesterol (mg/dl) 150.6 
HDL (mg/dl) 51 
LDL (mg/dl) 73 
VLDL (mg/dl) 26.6 
TG (mg/dl) 56 
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Services offered: Standardization and Characterization of AYUSH formulations 
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Sample ID C1MFH Code: 
 
BUN (mg/dl) 16.3 
Serum Creatinine (mg/dl) 0.7 
Total Bilirubin (mg/dl) 0.3 
SGOT (IU/ml) 112 
SGPT (IU/ml) 38 
Total cholesterol (mg/dl) 146.1 
HDL (mg/dl) 54 
LDL (mg/dl) 77 
VLDL (mg/dl) 15.1 
TG (mg/dl) 57 
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Sample ID C2MFB Code: 
 
BUN (mg/dl) 20.2 
Serum Creatinine (mg/dl) 0.8 
Total Bilirubin (mg/dl) 0.2 
SGOT (IU/ml) 126 
SGPT (IU/ml) 47 
Total cholesterol (mg/dl) 148 
HDL (mg/dl) 54 
LDL (mg/dl) 57 
VLDL (mg/dl) 37 
TG (mg/dl) 38 
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